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2. SUMMARY  
Diabetes mellitus places a considerable burden on patients in terms of morbidity and 
mortality and on society in terms of costs. The number of individuals with diabetes is 
estimated at 160 000 in Norway, 170 mill globally. These numbers are expected to increase 
considerably in the future. The objective of this thesis was to increase knowledge about the 
costs and cost-effectiveness of diabetes interventions. The first sub-study explored the 
economic costs of diabetes in Norway, the second analyzed HRQoL in patients with 
diabetes and the third explored the cost-effectiveness of a lifestyle intervention.   
 
Costs of diabetes 
Using the prevalence approach, we included costs of in-patient hospital services, out-
patient clinic visits, physician services, drugs, medical equipment, nutrition guidance, 
physiotherapy, acupuncture, foot therapy and indirect costs. Data were collected from 
national registers and responses to a survey of 584 individuals with diabetes. 
The total estimated cost of diabetes in Norway in the year 2005 was NOK4.2 
billion, which represents 2.4% of total national health care expenditure. The largest 
contributors to the costs were drugs, medical devices and hospital admissions. When 
hospital stays with diabetes as a secondary diagnosis were excluded, total costs were 
NOK2.49 billion. Pharmaceuticals accounted for NOK808 million (32%), disability 
pensions NOK408 million (16%), medical devices NOK340 million (14%) and hospital 
admissions NOK179 million (7%). Patient expenditures for acupuncture, physiotherapy 
and foot therapy were many times greater than those of nutritional guidance. Finally, the 
total costs of lost production from job absenteeism and premature mortality amounted to 
NOK596 million. 
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Health-related quality of life in diabetes 
The aim of this study was to explore the impact of diabetes complications on health-related 
quality of life (HRQoL). We used the responses from a mail survey performed in Norway 
and asked about demographics, diabetes related complications and HRQoL using the EQ-
5D descriptive system. The EQ-5D is a standardised instrument for use as a measure for 
health outcome. It is widely used, and by many governments a recommended instrument 
for measuring HRQoL. We explored the EQ-5D’s ability to capture and represent typical 
complications related to diabetes. 
 Individuals without any self-reported diabetes complications had HRQoL in the 
range 0.85-0.90 on a scale from 0 (death) to 1.0 (prefect health). HRQoL was largely 
dependent on the presence of major diabetes related complications. Complications with the 
most severe impact were stroke, ischemic heart disease and neuropathy.  
 
Cost-effectiveness of a diabetes intervention 
We estimated costs and health outcomes of lifestyle interventions by means of the British 
UKPDS Outcomes Model. Data on the impact of diet and exercise on diabetes risk factors 
(HbA1c, blood-pressure, cholesterol, and body weight) were taken from a Norwegian trial 
on individuals with poorly controlled type 2 diabetes. Cost and HRQoL data were taken 
from paper I and II.  
 With immediate switch to insulin the estimated discounted life expectancy was 9.44 
years (7.67 Quality Adjusted Life Expectancy (QALE)), while it was 9.48 (7.71 QALE), 
9.53 (7.75 QALE) and 9.64 years (7.86 QALE) for two years, five years and lifelong 
lifestyle intervention. The discounted lifetime total costs including indirect costs of the four 
programmes were NOK283,637, NOK512,540, NOK799,245 and NOK1,417,004, 
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respectively. Compared with immediate switch to insulin, the costs per additional life-year 
were NOK6,053,073, NOK6,209,362 and NOK5,832,427 for two-year, five-year and 
lifelong lifestyle intervention, respectively. When the cost of time related to travel and 
participation in the diet and exercise sessions were disregarded, the costs per incremental 
QALY for the respective treatment courses were NOK40,656, NOK55,277 and 
NOK33,649.  The results indicate that lifestyle interventions are not cost-effective unless 
society disregards indirect costs. 
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3. ABBREVIATIONS 
CEA      Cost-effectiveness analysis  
CHF      Congestive Heart Failure 
CMA      Cost-minimization analysis 
CUA      Cost-utility analysis 
HbA1c      Glycosylated hemoglobin 
HRQoL     Health-related quality of life  
IHD      Ischemic Heart Disease  
MAU instrument    Multiple Attribute Utility instrument 
MI      Myocardial Infarction 
NDA      Norwegian Diabetes Association 
NLWA     Norw. Labour and Welfare administration 
NOK      Norwegian crowns (currency) 
OBGLD     Oral blood glucose lowering drugs 
QALE      Quality adjusted life expectancy 
QALY      Quality adjusted life year 
QoL      Quality of Life 
SBP      Systolic blood pressure 
SF- 6      Short-form 6 
SF-36      Short-form 36 
SG       Standard gamble 
TTO      Time trade off  
VAS      Visual analogue scale 
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5. BACKGROUND 
 
5.1. Diabetes mellitus 
Diabetes mellitus is a disease characterized by inadequate insulin release and in type 2 
diabetes also insulin resistance, which lead to abnormally high plasma glucose levels. 
People with type 1 diabetes produce little or no insulin at all because the beta-cells in the 
pancreas have been destroyed by an autoimmune process. In early type 2 diabetes the 
pancreas continues to produce insulin, and insulin levels are often even higher than in non-
diabetic individuals. However, the insulin response after a meal is delayed and inadequate 
leading to compensatory increased plasma insulin concentrations during postprandial 
hyperglycaemia. The pathogenesis of hyperglycaemia and the insulin production in the 
body are illustrated in figures 1 and 2.   
 
Figure 1 Pathogenesis of hyperglycaemia  
 
Pathogenesis of Hyperglycemia
Type 2 Diabetes Mellitus: The Fed State
glucagon +
Insulin +
Adapted from Kahn SE, Porte D, Jr. In Porte D, Jr, Sherwin RS, eds.  
Ellenberg & Rifkin’s Diabetes Mellitus, 5th ed. 1997:487-512.
200
x
x
x
insulin -
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Figure 2 Simplistic model of the control of glucose metabolism 
 
 
 
Type 2 diabetes is associated with obesity, and the increasing number of obese 
people is believed to increase the incidence and prevalence of diabetes. The age/sex 
specific incidence seems to be increasing in industrialised countries (1) although some 
research question this view (2). At least some of the increase in the prevalence of diabetes 
may be a result of increased attention and changed diagnostic criteria. There is little doubt, 
however, that the real prevalence of type 2 diabetes in Norway will increase as a result of 
demographic changes with an aging population over the next 30 years1. 
 
 
 
                                                 
 
1 http://www.ssb.no/samfunnsspeilet/utg/200401/01/ 
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Diabetes complications (long and short term) 
Untreated diabetes may lead to symptoms such as excessive urination (polyuria), 
infections, abnormal thirst and drowsiness. In the long run diabetes constitutes a risk of 
micro- and macrovascular complications. The first type encompasses retinopathy, 
nephropathy and neuropathy (including autonomic neuropathy). Macrovascular disease 
affects the larger arteries impairing blood supply to the heart, brain and lower extremities. 
A special complication is diabetic foot ulcers that usually result from a combination of 
neuropathy and reduced blood supply. Another macrovascular complication is the 
development of aortic aneurisms. In addition to diabetes-related complications, episodes of 
treatment-induced hypoglycaemia, fear of hypoglycaemia, change in lifestyle and fear of 
long term consequences may lead to reduced quality of life among individuals with 
diabetes. 
The mixed pathophysiology entails a variety of clinical manifestations such as 
impaired vision, kidney failure, neuropathic pain, angina pectoris, myocardial infarction, 
stroke, ruptured aorta aneurisms and impaired circulation in the lower extremities 
(intermittent claudication, chronic leg and foot ulcers). Many of the complications require 
costly treatment such as renal replacement therapy and coronary interventions. 
 The clinical manifestations of diabetes lead to a loss of quality (3;4) and also 
quantity of life (5-9). Medical therapies such as renal replacement therapy, coronary 
intervention (PCI and CABG) lead to additional burdens for the patients. There is little 
doubt that diabetes leads to reduced health and further a significant loss in welfare to 
society. The reduced productivity following the increased morbidity and mortality adds to 
the burden of patients and society. 
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Figure 3 Overview of where diabetes-related complications may occur in the body      
 
 
Source: healthline.com 
 
Prevalence and incidence 
The prevalence of type 2 diabetes is increasing in many countries (1) including Norway 
(10). The total number of persons with diabetes worldwide is projected to rise from about 
170 million in 2000 to about 370 million in 2030 (1). The number of persons with 
diagnosed diabetes in Norway is estimated to be 90.000 - 120.000 of which most have type 
2 diabetes (11). We have performed our own estimate based on the following. In Norway 
the number of patients with type 1 diabetes has been estimated at 25,000 (11). In 2005, 
117,600 persons in Norway were treated with insulin or oral antidiabetics (information 
from Norwegian Prescription Database, searchable database). Based on this we assume that 
92,600 of them have type 2 diabetes. In the Norwegian HUNT study (12) the proportion of 
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patients with type 2 diabetes that was not on antidiabetic pharmaceuticals, was 30%. This 
would imply that the total number of patients with type 2 diabetes is 132,300 (92,600/0.7) 
(11-14). Additionally, 30-50% of persons with type 2 diabetes are assumed to be 
undiagnosed. It has been estimated that about 3-4% of the population above the age of 30 
have type 2 diabetes. 
 
Figure 4   Projected global prevalence of diabetes in 2025 
 
 
Treatment of diabetes  
A range of interventions are available in the treatment of diabetes to prevent or postpone 
complications. In addition to blood glucose lowering therapies, various treatment aiming at 
preventing complications are essential. Most important are blood pressure lowering and 
lipid lowering agents. For type 1 diabetes the main medicines for regulating blood glucose 
levels are different types of insulin.  
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 In type 2 diabetes patients the first step in the treatment is counselling on diet and 
physical exercise. The next step is to administer oral blood glucose lowering drugs 
(OBGLD), where metformin is considered as first-line therapy in Norway as well as in 
other Western countries. Subsequently, other OBGLDs with or without supplement of 
insulin may be applied (15). 
 
Figure 5     Example of a diabetes-treatment algorithm 
  
 
 
Effect of diabetes treatments 
The effects of blood glucose controlling diabetes treatment are usually measured in so 
called intermediate terms such as glycosylated haemoglobin that reflects mean blood 
glucose levels during recent 2-3 months. From the literature we can find data on the 
consequences of having uncontrolled blood glucose levels over longer time periods. Such 
consequences may be short term complications (symptoms directly caused by hyper- or 
hypoglycaemic episodes) and long term complications (micro- and macrovascular) and loss 
of life years. Long term complications may lead to decreased quality of life. Methods of 
measuring quality of life, or in our context, health-related quality of life (more on this 
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below) have been developed and are widely used and adapted in quantifying effect of 
treatments. 
 
5.2. Health Economics and diabetes 
Limited health care resources and new and costly treatments have led to increasing demand 
among decision makers for documentation of “value for money” for new treatments. New 
tools for economic evaluation, and methods to analyze uncertainty, have been developed. 
When developing economic analyses of health interventions, analysts have to draw on data 
from numerous sources and synthesize them in a health economic evaluation. The two 
principal inputs in such analyses are costs and effect. For a complex disease such as 
diabetes the main goal of treatments is related to obtain stable and controlled levels of 
blood glucose and consequently quality of life. At the time when a new treatment reaches 
the market, there is usually little knowledge of long term costs and effect. This is 
particularly the case in diabetes because trials with clinical relevant outcomes (“hard 
outcomes”) require long term follow-up. New interventions are therefore usually approved 
on the basis of surrogate endpoints such as HbA1c. This means that economic evaluation of 
diabetes interventions (drugs, lifestyle changes, etc) almost always have to be based on 
projections from surrogate endpoints to clinical relevant endpoints and subsequently to life 
years or QALYs.  
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6. AIMS AND OBJECTIVES 
Against this background this thesis aims as generating knowledge about costs and health-
related quality of life (HRQoL) related to diabetes and to perform a cost-effectiveness 
analysis of a specific intervention. 
 
The aims of this thesis were threefold: 
 
- To quantify the societal costs of diabetes in Norway and to provide researchers with 
a comprehensive set of unit costs for use in economic analyses. 
 
- To investigate diabetes related determinants of HRQoL 
 
- To estimate the costs and health consequences of a lifestyle intervention versus 
insulin in a group of poorly controlled type 2 diabetic patients.  
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7. THEORETICAL FOUNDATIONS 
 
 
7.1. Cost-of-illness 
Cost-of-illness analysis (COI) is a type of study that has been designed to quantify and 
value all economic consequences of a disease without taking into account the benefits of 
any treatment. In a COI analysis there is no measure of severity of disease or effects and 
side effects of treatments. Therefore, COI analysis in itself cannot guide priority setting, 
but may be useful in funding of health services and setting priorities for research. 
Furthermore repeated analyses undertaken at different points in time may be useful to 
monitor changes in resource use related to a disease. 
There are two main approaches to COI analysis: the prevalence (16-20) and the 
incidence approach (21). The former approach accounts for all prevention, treatment and 
rehabilitation costs incurred during a given year. The prevalence approach has the 
advantage of relating to measures of total annual health care expenditure, and it may yield 
more accurate estimates because it is based, at least in principle, on observed costs rather 
than projected ones. With the incidence approach, all costs for new cases of the disease in a 
given year (the index year) are measured. Future treatment costs are accounted for by 
estimating the future costs for all patients who develop the disease in the index year, and 
the present value of the costs are added to the costs incurred in the index year.  The 
advantage of the incidence approach lies in the fact that it provides projections of future 
costs that may be very different from current ones when incidence is increasing or 
declining. Such projections, however, may be uncertain (22). 
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7.2. Cost-effectiveness analysis (CEA) 
In order to consider the cost-effectiveness of a health intervention it has to be compared 
with another intervention. The comparator may be no treatment, but it should be noted that 
even no treatment may entail resource use and health consequences.  
 The simplest form of cost-effectiveness analysis is the cost-minimization analysis 
(CMA). In this form of analysis the effects of the compared treatments are the same, or 
assumed to be the same, and only the costs are analysed and compared. Cost-effectiveness 
analysis implies comparing both costs and effect. When effects have a common 
denominator incremental cost-effectiveness is expressed with the incremental cost-
effectiveness ratio (ICER) shown in figure 6. 
 
Figure 6    The formula for calculating the incremental cost-effectiveness ratio (ICER) 
 
EFFECT
COSTS
EFFECTEFFECT
COSTCOSTS
ICER
BTreatmentATreatment
BTreatmentATreatment






__
*_*_
 
*Treatment A is new treatment and treatment B is the comparator (examples: standard treatment, best option 
or cheapest option)   
 
When the common denominator/effect is expressed in terms of quality-adjusted life 
years (QALY) the analysis is sometimes called cost-utility analysis (CUA). Figure 7, below 
illustrates when cost-effectiveness analysis or cost-utility analysis is required. 
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Figure 7    Choice of treatment and use of economic analysis according to costs and effect of treatment 
 
 
EFFECT OF TREATMENT 
NEW BETTER EQUAL OLD BETTER 
COST OF 
TREATMENT 
NEW CHEAPER 
CHOOSE NEW 
(NEW DOMINATING) 
CHOOSE NEW 
CMA 
CEA/CUA 
EQUAL CHOOSE NEW INDIFFERENT CHOOSE OLD 
OLD CHEAPER CEA/CUA 
CHOOSE OLD 
CMA 
CHOOSE OLD 
(OLD DOMINATING) 
 
The ICER is an expression of the additional, incremental costs per extra unit of 
health of one treatment compared with another treatment or no treatment. The ICER value 
can be used by decision makers for priority setting. In principle, the production of health 
will be maximised by selecting treatments with increasing ICER’s until the budget is 
exhausted. The ICER of the last treatment (the treatment with the highest cost per unit of 
outcome ratio) to be selected is called the threshold ICER. If the health care budget 
increases, treatments with higher ICER’s may be selected, and vice versa, if the budget 
decreases, only the interventions with the highest value for money, the lowest ICER’s can 
be selected. In practice, the ICER is compared with a threshold ICER. This threshold 
reflects the maximum cost per unit of outcome that the funder (government/insurance-
company) is willing to pay for health improvements. If a treatment has an ICER below this 
threshold value, treatment is likely to be accepted by the funder and a treatment with a ratio 
over this threshold is likely to be refused. Treatments can be ranked from the lowest to the 
highest ICER in a so-called league table. 
 Prioritising based on ICER’s implies that maximizing the production of health is the 
main or only goal of the health policy. However, in practice other considerations are taken 
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when prioritising, in particular considerations of equity, distribution of health and severity 
of disease. 
 When performing cost-utility analysis, the effect is measured in QALY’s, described 
in section 6.4 below. This type of analysis has the welcome feature of incorporation both 
length of life and quality of life in one single measure and it allows decision makers to 
compare cost-effectiveness of treatments across different diagnoses and therapeutic areas. 
 
7.3. Modelling 
Clinical trials often have too short duration for adequate economic evaluation. Furthermore 
the output in clinical trials are often expressed in so called intermediate or surrogate 
endpoints such as HbA1c, mmHg, cholesterol level and others. In order to estimate cost-
effectiveness in a relevant time perspective and using clinical relevant endpoint such as life 
years saved, quality of life, avoided fractures etc, modelling is needed in order to capture 
long term costs and outcomes. By extrapolating in time, place or patient groups, we aim to 
account for all costs in a relevant time perspective, adjusting costs and effect to present 
value (discounting). 
 
Techniques used in health economic modelling: 
1) Decision trees: This is a relatively simple form of decision analysis. The first branches 
of the tree usually represent strategies. The next branches illustrate different outcomes 
with probabilities attached. This may lead to further treatment options, also with 
probabilities attached. At the end of the final branches both costs and the “pay-off”, or 
expected outcomes are denoted (this may be health status value or probability of 
survival. By “rolling back” the decision tree or calculating the expected value by 
multiplying probabilities throughout the tree and multiply this with both costs and the 
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pay-offs, one estimates the expected costs and expected value of each treatment 
strategy. These data enable an estimation of the ICER. This will so forth aid the 
decision maker when choosing treatment strategy. 
 
Figure 8   Decision tree (example for illustration) 
 
 
 
2) Markov models: This is a more complicated type of decision analytic tool that accounts 
explicitly for time. A Markov model encompasses a set different health states and may 
include a health state for healthy and one for dead. The health state “dead” is often 
called the terminal or the absorbing state. In a Markov model the subjects in the model 
may move from “healthy” to “sick” and back to “healthy” again. In all health states the 
patient has certain probability of staying in the same state or moving to another.  In the 
figure below, being in the health state “healthy” implies a probability of staying 
healthy, a probability of incurring gastritis, a probability of incurring an ulcer and 
finally a probability of dying. Individuals are at risk of moving to another state at fixed 
time intervals – the so called cycle length. The choice of cycle length depends on the 
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decision problem. A cycle length of one year is frequently used, but may be much 
shorter depending on the decision problem. Typically a move from healthy to 
“gastritis” would increase the probability of moving to “ulcer” or “dead”. Being in a 
health state may involve a cost and a health state score. Often a Markov model starts 
out with a cohort of subjects and is run in cycles until all subjects are in the absorbing 
state, “dead”. If a model is run multiple times with different probabilities associated to 
the transition between states (these probabilities may be derived from clinical trials) it 
is possible to analyse the difference in costs and health effects and calculate the 
associated ICER. A disadvantage of Markov models is that it is “history-less” (do not 
account for time and events in previous states). The impact of history on future costs 
and outcomes can be handled by creating new states that depend on previous events or 
states. This, however, increases the number of states in the model, sometimes to such 
an extent that the model may become difficult to handle. This issue may especially arise 
when applied in health economics due to the nature of health and disease, especially 
chronic disease, where disease history may greatly influence future health.  
 
Figure 9   Markov model (example for illustration) 
 
Healthy
DeadUlcer
Gastritis
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A Markov model is typically populated with a cohort of individuals and run in cycles until 
all individuals are in an absorbing health state (typically “dead”). 
 
3) Microsimulation: Sometimes modelling time-varying patient characteristics is required 
in decision analyses. Microsimulation models are individual-based, simulating single 
individuals going through the model. These models utilize first-order Monte Carlo 
simulation to enable tracking of each simulated individuals history, which reduces the 
number of health states in the model. First-order Monte Carlo simulation may be 
described as running random trials and the draw of random numbers to decide a single 
path through the model. A disadvantage, that becomes less apparent with development 
within computer technology, is that these models require large computational resources 
and may take long time to run. An example of a microsimulation model is the UKPDS 
Outcomes Model, which was used in Paper III. The UKPDS Outcomes Model is an 
individual-level model developed to estimate long-term impact of health interventions 
for people with type 2 diabetes (23). 
 
Figure 10 State-transition models (example for illustration) 
 
 
Source: DRAFT – State-Transition Modelling: A Report of the ISPOR-SMDM Modelling Good Research 
Practices Task Force Working Group -Part 5, Siebert and colleagues. Available at 
www.ispor.org/workpaper/modeling_methods/DRAFT_Modeling-Task-Force_State-Transition-Modeling-
Report.pdf 
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7.4. Cost-utility analysis and health-related quality of life (HRQoL) 
The concept of quality of life (QoL) is a widely debated theme. What is QoL? Are we 
really measuring QoL or are we merely providing a measure for health status? Who should 
have a say when measuring quality of life? No general definition of QoL has been accepted 
or adapted. Despite the absence of a general definition of QoL there is a consensus that 
QoL is multidimensional, subjective and dynamic. Multidimensionality means that 
physical, psychological and social aspects are considered. Subjectivity means that a person 
should think about their own preferences and health status when measuring their own QoL. 
That QoL is dynamic means that it changes over time. Statements about quality of life are 
likely to be influenced by factors such as income, history and self interest of the individual. 
This raises the issue of the validity of the responses obtained. 
 In the context of economic evaluation we are primarily interested in HRQoL, this is 
a pure measure of health and functional status of the individual and excludes factors such 
as happiness and financial situation.   
 In order to obtain information on preferences of different health states and how a 
health state is valued, different techniques have been used. Preference-based methods such 
as the time trade-off method (TTO)(24;25), standard gamble (SG)(24) or the visual 
analogue scale (VAS) have been used in samples of individuals, aiming to derive utilities 
that can represent an entire population. 
 
Time Trade-off 
The time trade-off method is a technique where an individual is asked to imagine having a 
health problem lasting for a specific number of years. The question is then how many years 
in a reduced health state the individual is willing to sacrifice in order to obtain perfect 
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health. In other words, how much time is an individual willing to trade off in order to gain 
perfect health? This approach is illustrated by equation 1 and figure 11. The capital T is 
time in the state of reduced health, small h is the unknown value, on the 0 – 1 scale, of the 
reduced health state. Small h is the value we are searching for in this exercise. Capital H is 
the known value of perfect health, 1. Small t is the capital T minus the number of years the 
individual is willing to sacrifice to gain perfect health.         
 
Equation 1   Value of a particular health state based on time-trade-off method (see figure below) 
(h=value of health state in question, H=value of perfect health, T=time in the health state in question, 
t=equivalent time in perfect health)  
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Figure 11    Graphic representation of the time-trade-off method (example for illustration) 
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Standard gamble 
In this approach the individual is asked to imagine being in a state of reduced health (often 
described extensively) the rest of his/hers remaining life years. The next step is to imagine 
participating in a lottery, a gamble. The possible outcomes of this gamble are firstly the rest 
of the remaining life years in a state of perfect health and secondly immediate death (see 
figure below). The probabilities (p) in the gamble are varied until the individual is 
indifferent between being in the reduced health state and taking part in the lottery. If the 
individual is willing to take part in the lottery with a 0.9 chance of perfect health (and thus 
a 0.1 chance of immediate death), the value of the reduced health state is 0.9. 
 
 
Figure 12   Graphic illustration of a standard gamble (example for illustration) 
 
 
 
 
Rating scale (RS) or visual analogue scale (VAS)  
This technique is the simplest form of eliciting preferences for health states. The exercise 
can be performed in different ways but basically the individual is asked to place different 
health states (often described in detail) on a scale (“thermometer”) ranging from 0 to 100 (0 
being death and 100 being perfect health) (see figure below). If one of the described health 
states is placed on 90 it means that this health state is considered to have the value of 0.9.  
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Figure 13   The rating scale (example for illustration) 
 
 
Health-related quality of life instruments 
The techniques described above are time consuming and complicated to administer. In 
practice, HRQoL instruments are most frequently used. There are three main approaches 
when describing and measuring HRQoL: Disease-specific instruments, generic instruments 
and utility instruments. Numerous disease-specific HRQoL measures exist for diabetes and 
score HRQoL on ordinal scales. Examples of such instruments are Diabetes Care Profile 
(DCP) (26), Audit of Diabetes-Dependent Quality of Life (ADDQoL) (27). These 
instruments are not useful as a single measure in cost-effectiveness analysis but may serve 
an important role of capturing diabetes specific features of treatment and effects. 
 Generic instruments such as the Short Form 36 (SF-36) (28) capture  HRQoL and 
contains 36 items along 8 dimensions. Health profiles from SF-36 cannot be used directly 
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in economic evaluation, but John Brazier has developed methods to translate SF-36 profiles 
into utilities (30-33).   
 In multi-attribute-utility instruments (MAU), such as the EQ-5D (29), 15D (30), 
Health Utility index (HUI) (31;32) and SF-6D, which is a simplified version of SF-36,  the 
respondents indicate levels of health problems on a number of dimensions of health. This 
can be done in a personal interview, telephone interview or by personally filling out a form. 
The questionnaire responses describe the health profile of the individual. These profiles 
capture different dimensions of health and can be translated into an index on a zero-one 
scale where zero denotes dead and one perfect health. In some instruments it is also 
possible to have values lower than zero. Such a value indicates a health state considered 
worse than death. Health status values are much debated (33-38).  The translation of the 
scores from questionnaires into a single value representing an individual’s health status 
index, are done by algorithms and value sets derived from population surveys (described 
above).   
 EQ-5D is a MAU instrument with five dimensions (MOBILITY, SELF-CARE, 
USUAL ACTIVITES, PAIN/DISCOMFOR and ANXIETY/DEPRESSION) and three 
levels on each dimension (“no-, some- and extreme problems”), and has previously been 
used in studies of diabetes (39). EQ-5D has been used extensively in economic evaluation. 
The EQ-5D is much debated because of its limited descriptive system and the possibility of 
health states worse than death (33-38). The EQ-5D is, despite the criticism, recommended 
for use in cost-effectiveness analyses by institutions such as the National Institute for 
Clinical Excellence (NICE) in the UK and the Health Care Insurance Board in the 
Netherlands. Therefore, researchers working with economic evaluation, health care workers 
and the pharmaceutical industry need easy access to utility data for different types of 
patients.  
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Quality Adjusted Life Years (QALYs) 
When HRQoL weights (derived by TTO, SG, RS or MAU-instruments) are multiplied with 
duration (years, months, duration of effect, expected remaining life years) the product is 
named QALY (quality-adjusted life years) (se figure below).  
 
Figure 14   Graphic illustration of one QALY (example for illustration) 
 
 
 
 
 
 
 
 
 
 
 
 
QALYs can be calculated for different patient groups to compare for example 
effectiveness of treatment, enabling health improvements and life extensions to be captured 
in one single variable.  
 The concept of the QALY is based on a set of assumptions In a study by Weinstein 
and colleagues (40) the underlying assumptions of the conventional QALY approach are 
listed. 
1. A resource-allocation decision must be made. 
2. The outcomes of the alternatives can be specified in terms of health states, changes, and 
durations. 
 
 Health status 
0 
1
Y
1
One life-year 
1 QALY 
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3. Resources are limited, and each alternative has resource implications (costs). 
4. A major objective of the decision-maker is to maximize health of the population, subject 
to resource constraints. 
5. Health is defined as value-weighted time (QALYs) over the relevant time horizon. 
6. Value is measured in terms of preference (desirability). 
7. Each individual is risk neutral with respect to longevity and has utility that is additive 
across time. 
8. Value scores (preferences) measured across individuals can be aggregated and used for 
the group 
9. QALYs can be aggregated across individuals; i.e., a QALY is a QALY regardless of 
who gains/lose it 
 
7.5. Regression 
Logistic regression 
Multinomial logistic regression refers to at setting with more than two possible outcomes, 
for example “no problems”, “some problems” or “extreme problems”. Binary logistic 
regression, also called binominal, may be applied when there are only two outcomes, for 
example “no problems” or “some problems”. For ease of interpretation the outcomes are 
usually coded “0” (no problems) and “1” (some problems). The binary logistic regression is 
based on the assumption that the log of odds of the outcome is a linear function of a set of 
independent variables: 
 
Equation 3   The model for logistic regression when facing binary outcomes (example for illustration) 
 

  	     
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Note:  gives the odds that a code of 1 will occur in the sample on any one opportunity. 
Logistic regression is a transformation of the dependant variable to the log odds ratio. 
An example may be predicting whether a person reports having a mobility problem 
(EQ-5D mobility dimension) based on the presence of different co-morbidities. 
 
Robust linear regression 
The aim of regression analysis is to explore the relationship between one or more 
independent variables and a dependent variable. Ordinary least squares regression (OLS) is 
a commonly used method of regression and is based on the assumption that the dependent 
variable is a linear function of one or more independent variables. If the assumptions 
behind OLS are fulfilled OLS may be considered a preferred choice of regression model 
because it is relatively robust and because of computational ease. The main assumptions 
are:  the model is linear in parameters, data are a random sample of the population, the 
errors are statistically independent from one another, the expected value of the errors is 
always zero, the independent variables are not too strongly correlated, the independent 
variables are measured precisely, the residuals have constant variance and that the error 
terms are normally distributed. When any of those assumptions are not fulfilled, OLS may 
yield biased coefficients. An assumption in a homoscedastic model is that the variance of 
the error term is constant for all values of x. However, for many real data sets, 
heteroscedasticity is the reality. Heteroscedasticity implies that the variance of the error 
terms is dependent upon x. The consequence is biased regression coefficients. Robust 
regression is a useful alternative to linear regression which means absolute error is 
minimized instead of mean squared as in linear regression. Robust regression usually 
means linear regression with robust (Huber-White) standard errors which means relaxing 
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the assumption of homoskedasticity. The effect of using White’s correction is that in 
general the standard errors for the slope coefficients are increased relative to the usual OLS 
standard errors. This makes for more conservative hypothesis testing, so that more 
evidence against the null hypothesis would be needed before we would reject it. 
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8. ECONOMIC STUDIES OF DIABETES AND DIABETES INTERVENTIONS 
 
8.1. Cost-of illness 
In order to get an overview of the literature of interest we did a search (per 30.06.12) in 
PubMed with the search terms “Cost of Illness"[Mesh] AND diabetes”, limited to 
encompass reviews and systematic reviews. This search returned 240 articles. Studies of 
interest were studies of type 1 or type 2 diabetes, or both together. Both direct and indirect 
costs should be addressed. The language should be English, Swedish, Norwegian or 
Danish. After screening through the 240 titles 25 studies were kept. After screening the 
abstracts of the 25 studies four were kept. 
The latest study in a series of COI-analyses performed by the American Diabetes 
Association was published in 2007 (17). The study turned up in our search even though it is 
not a review of existing literature. The objectives of the study was to quantify the economic 
burden of diabetes caused by increased health resource use and lost productivity, and to 
provide a detailed breakdown of the costs attributed to diabetes. The study used a 
prevalence-based approach that combined the demographics of the population in 2007 with 
diabetes prevalence rates and other epidemiological data, health care costs, and economic 
data into a Cost of Diabetes Model. Health resource use and associated medical costs were 
analyzed by age, sex, type of medical condition, and health resource category. Data sources 
included national surveys and claims databases, as well as a proprietary database that 
contained annual medical claims for 16.3 million people in 2006. The total costs of 
diabetes in 2007 were estimated to $174 billion. Excess medical expenditures and reduced 
national productivity accounted for $116 billion and $58 billion, respectively. Medical 
costs attributed to diabetes include $27 billion for care to directly treat diabetes, $58 billion 
to treat the portion of diabetes-related chronic complications that are attributed to diabetes, 
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and $31 billon in excess general medical costs. The largest components of medical 
expenditures attributed to diabetes are hospital inpatient care (50% of total cost), diabetes 
medication and supplies (12%), retail prescriptions to treat complications of diabetes 
(11%), and physician office visits (9%). The authors draw the conclusions that the actual 
national burden of diabetes is likely to exceed the $174 billion estimate. The reason stated 
is that the social intangible costs associated with pain and suffering, care provided by 
nonpaid caregivers, excess medical costs associated with undiagnosed diabetes, and 
diabetes-attributed costs for health care expenditures categories omitted from the study. 
Expenditure categories such as health care system administrative costs, over-the-counter 
medications, clinician training programs, and research and infrastructure development were 
also omitted from the analysis.  
Several authors point to a 2004 review by Ettaro (41). The review examines the 
results of COI studies performed over the last three decades, identifies the strengths and 
limitations of the various methods utilized, and suggests future research that will help 
determine the economic burden of diabetes more accurately. The economic cost of diabetes 
is estimated to be as much as dollars US100 billion per year in the US alone (1997 values). 
The estimated cost has increased notably over time, primarily due to price inflation and the 
increasing prevalence of diabetes. Cost estimates are significantly influenced by differences 
in methodologies. This makes comparisons between COI studies difficult. The authors 
claim that in order to capture the costs associated with diabetes-related complications later 
studies have included costs related to diabetes as a secondary or tertiary diagnosis using the 
attributable risk methodology. Attempts at capturing these secondary costs are appropriate 
because of the long-term complications associated with diabetes. The authors suggest that 
future research efforts should focus on refining methods to estimate costs, improving the 
interpretation of study findings, and facilitating comparisons between studies. 
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Pagano and co-authors in 1999 presented a review (42) of studies on the costs of 
diabetes and its complications. In short, the authors find that many studies did not give 
technical details, so it was hard to understand the methods. Methodological choices varied 
widely between the studies. This is probably due to the lack of consensus on the 
methodology of COI studies. Pagano concludes that a general consensus on COI studies is 
still remote, making the value of any comparison of results questionable. 
A study from 1992 by Leese (43) aim to presents a review of studies which have 
been carried out on the costs of diabetes and its complications. The study gives us some 
insight into what researchers found 20 years ago. The authors refers to a study that found 
that treatment of the disease and its complications takes up 4-5% of total health care 
expenditure in the U.K, costs are dominated by in-patient care for the complications arising 
from diabetes. The authors find it surprising that costs have not been more extensively 
researched for a chronic and potentially disabling disease with numerous complications 
such as diabetes. A large amount of data is available about the implications of diabetes in 
terms of incidence and prevalence. Little data on costs have been collected, particularly 
indirect and marginal costs. The authors claim that both insulin dependent and non-insulin 
dependent diabetic patients exhibit similar complications so that the cost of treatment may 
be comparable, but further studies are needed to establish this. Furthermore, apparently, 
few studies had included diabetes as a secondary diagnosis. The studies that were available 
at the time focused on direct costs. This is claimed to be so because they are the easiest to 
measure. Fewer studies included indirect costs, such as the effect of time lost from work, 
early retirement and premature death. Again, this is claimed to be a result of the difficulties 
in assigning monetary values to these factors. Finally the authors conclude that the most 
important contributors to the costs of diabetes are those of treating complications such as 
eye and limb disease, heart disease, neuropathy and nephropathy. 
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In a second search we looked specifically for diabetes related COI-research 
performed in the Nordic countries. We included studies of type 1 as well as type 2 diabetes, 
but excluded studies that did not encompass direct as well as indirect costs.  The PubMed 
search resulted in the following: 
- "Cost of Illness"[Mesh] AND diabetes AND Denmark. The search returned eleven 
studies of which none was considered relevant. 
- "Cost of Illness"[Mesh] AND diabetes AND Finland. The search resulted in only 
six studies of which none was considered relevant.  
- "Cost of Illness"[Mesh] AND diabetes AND Norway. This search returned six 
titles, but only one was relevant (Paper I in this thesis).  
- Cost of Illness"[Mesh] AND diabetes AND Sweden. The PubMed search resulted 
in 36 studies. Among these, three were considered relevant to the questions 
discussed in this thesis.   
 
The most recent Swedish study was from 2009 (44). The aim of the study was to 
estimate healthcare cost and productivity losses as a result of diabetes and diabetes-related 
chronic complications in Sweden in 1987 and 2005. Estimates on attributable relative risks 
and age-specific diabetes-prevalence rates were used to calculate the proportions of 
diabetes-related chronic complications that are attributable to diabetes. These attributable 
risks were applied to cost estimates for diabetes-related chronic complications based on 
data from population registers. The authors estimated total diabetes-related costs for 
Sweden in 1987 and 2005 to be EUR439m and EUR920m, respectively. Price estimates for 
1987 were adjusted to a 2005 price level. The increase of 110% for the period 1987-2005 
was estimated to stem from a 69% increase in the prevalence of diabetes (from 150,000 
diabetes patients (1.8% of the population) in 1987 to 254,000 (2.8%) in 2005) and of an 
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increase in the estimated annual cost per person diagnosed with diabetes by 24%. 
Healthcare accounted for 45% of the estimated cost in 1987 and for 37% in 2005. The 
estimated diabetes-related healthcare costs accounted for approximately 1.0% of total 
health care cost in Sweden in 1987 and for 1.4% in 2005. Diabetes per se, excluding costs 
of diabetes-related chronic complications (also estimated in the study) accounted for 57% 
of the diabetes-related healthcare cost in 1987 and for 50% in 2005. Cardiovascular disease 
was the complication with the largest impact on diabetes-related healthcare costs, 
contributing to 33% of the healthcare cost, 27% of the productivity loss and 82% of deaths 
in 1987. The respective figures for 2005 were 34, 24 and 65%. The conclusion of the study 
is that the cost of diabetes is substantial and increasing even in a fairly low-prevalence 
country such as Sweden.  
Another Swedish study (45) aimed to determine costs-of illness, including 
complications for adult diabetes mellitus. The source of study-participants was a previously 
conducted multicentre, cross-sectional study in which 1,861 patients were identified as 
having diabetes. A total of 1,677 of these agreed to participate in a cost-of illness study. 
Data were collected with interviews, systematic review of all available medical records. 
Co-morbidity was registered from all known medical records of health care. The average 
annual direct and indirect costs for an adult with diabetes were calculated to be Swedish 
crowns (SEK) 61,700 or 2.5 times higher than earlier estimates. The incremental cost per 
year of diabetes was 34,100 SEK. Direct health-care costs, defined as costs of out- and in-
patient care accounted for 33% of the incremental costs. Costs for municipality services 
and home help from relatives (defined as services concerning food, alarm, cleaning and 
others) corresponded to 24%. Indirect costs were defined as lost productivity because of 
temporary impairment from sickness (sick-days) and permanent impairment (early 
retirement before 65 years)) and accounted for 43%. The authors raise the issue of 
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underestimation of diabetes costs if co-morbidity caused by diabetes is not accounted for. 
And finally they find that when related complications are included to identify the actual 
burden of disease to society, the cost COI is substantially higher than previously estimated. 
Henriksson and co-workers aimed to estimate the total cost of diabetes mellitus in 
Sweden in 1994 and compare with former Swedish and American studies (19). The 1994 
economic burden of diabetes mellitus in Sweden was estimated at 5,746 MSEK (1US$ = 
7.50 SEK at the time of the study). The direct costs were estimated at 2,455 MSEK and 
constituted for about 43% of total cost. The indirect costs (production loss due to morbidity 
and premature mortality) were the dominant costs and amounted to 3,291 MSEK, or 57% 
of total cost. The comparisons with a previous Swedish study from 1978 indicated that the 
distribution of direct and indirect costs was about unchanged. The distribution of costs 
between management/control of the disease and complications was about the same for the 
two years. Four American studies showed a similar cost structure.  
 
8.2. Quality of Life 
For a search in PubMed we set a filter to languages English, Norwegian, Danish or 
Swedish. Searching PubMed with the search terms "Quality of Life"[Mesh] AND 
Diabetes” resulted in 3,617 studies. Furthermore, we restricted the search to include three 
instruments for measuring health related quality of life, the EQ-5D, SF-6D and the 15D. 
These instruments are of interest in the Norwegian setting as they are mentioned in the 
guidelines2 for pharmacoeconomic analyses from the Norwegian Medicines Agency 
(NoMA). A search was performed for each of the three instruments. The criteria for 
including studies were: a aim of the study was to measure impact of diabetes related 
complications on health related quality of life among persons with type 1 or type 2 diabetes 
                                                 
 
2 In Norwegian: www.legemiddelverket.no/upload/165659/11-08350-
28%20Endelige%20reviderte%20retninglinjer%201%20%20mars%202012%20docx%20222688.pdf 
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(pre-diabetes, metabolic syndrome were not included), and use of the EQ-5D, 15D or SF-
6D instruments. The following searches were performed: 
- "Quality of Life"[Mesh] AND Diabetes AND EQ-5D. The search resulted in 85 
studies among which 79 did not meet the inclusion criteria. 
- "Quality of Life"[Mesh] AND Diabetes AND SF-6D. The search returned 11 
studies among which ten did not meet the inclusion criteria. 
- "Quality of Life"[Mesh] AND diabetes AND 15D. The search resulted in nine 
studies among which six did not meet the inclusion criteria  
 
Among the six papers related to HRQoL, diabetes and EQ-5D, four were about type 
2 diabetes (3;46-48), one did not make a distinction between type 1 and 2 diabetes (49) and 
one compared both types (50) (Paper II of this thesis). 
One recent study (47) aimed to estimate the disutility related to experiencing a 
diabetes-related complication. The EQ-5D was administered to 1,147 Canadians with type 
2 diabetes. The authors controlled for age, gender and duration of diabetes. Changes in 
utility values were estimated by Ordinary Least Squares regression of EQ-5D scores onto 
binary indicators for the presence of an event. Mean utility value for all patients, patients 
without complications and patients with at least one complication was 0.75, 0.76 and 0.70, 
respectively. Age and male gender was associated with higher utility values. Amputation, 
myocardial infarction, stroke and kidney failure were all related to significant reductions in 
utility. The respective coefficients for the before-mentioned clinical events were: -0.0631, -
0.0586, -0.0462 and -0.01018. Kidney failure has the greatest negative impact on patients’ 
HRQoL of the clinical events covered in the study. 
A study of 220 Japanese patients with type 2 diabetes (48), used a Japanese version 
of the EQ-5D value set. The authors adjusted for age and sex before statistical analyses. 
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There was no significant relationship between EQ-5D scores and the presence of 
complications (neuropathy, retinopathy, nephropathy and lower extremity lesions). 
However the mean EQ-5D score was lower in patients with at least one complication (0.85) 
than in those without complications (0.88), but not statistically significant. The authors 
suggest that EQ-5D, which they claim is less sensitive than disease specific scales, should 
be used together with a disease specific scale for clinical evaluation. 
In a 2002 UK study by Clarke and co-workers (46), the authors used data from 
3,667 type 2 diabetes patients in UKPDS. Utilizing a Tobit model, the authors found that 
myocardial infarction, blindness in one eye, ischemic heart disease, heart failure, stroke and 
amputation  reduced the HRQoL by respectively: -0.055, -0.074, -0.090,  -0.108, -0.164 
and -0.280.  
In a study across five European countries (3) the aim was to gain insight into the 
impact of type 2 diabetes from the perspective of the patient. A total of 4,189 individuals 
were subjected to the EQ-5D questionnaire. The average score was 0.69 which is lower 
than score of healthy population in the United Kingdom with the same age. The mean 
values were higher (0.76) in the absence of complications. The presence of micro- and 
macrovascular complications impacted HRQoL negatively with scores of respectively 0.69 
for both. Having both complications reduced the quality of life score to 0.59. Independent 
predictors of reduced HRQoL were explored in a multivariate analysis. Predictors, in order 
of importance were gender, complications, treatment type, age, obesity and 
hyperglycaemia. The authors conclude that the implication for policy-makers is that 
preventing or reducing the complications of diabetes is the key to improving patient 
HRQoL.  
The aim of a US study (49) was to examine and quantify the differences in HRQoL 
of diabetic patients with and without macrovascular comorbid conditions. The study did not 
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distinguish between type 1 and type 2 diabetes. After controlling for age, sex, race, 
ethnicity, education, income, employment status, health insurance, smoking status, diabetes 
severity, and comorbidities, a two-part model was used to identify the relationship between 
macrovascular comorbid conditions and the EQ-5D index. Controlling for differences in 
sociodemographics, smoking status, diabetes severity, and comorbidities, the authors found 
that patients with macrovascular comorbid conditions had significantly lower EQ-5D index 
value of -0.062, compared to diabetic patients without these complications. The authors 
claim that the results of the study will be valuable for future comparative effectiveness and 
cost-effectiveness analyses in diabetes. 
The one study using (51) SF-6D was a Greek study which compared the sensitivity 
of EQ-5D, SF-6D and the 15D to the specific effect of diabetes complications. On two 
different locations in Greece, physicians interviewed patients during routine visits to a 
diabetological outpatient department. The 319 patients were interviewed with the EQ-5D, 
SF-6D and the 15D. Furthermore the patients were asked about socio-demograpic- and 
diabetes-related factors. Coronary heart disease and diabetic retinopathy were chosen for 
further analysis. Significant EQ-5D, SF-6D and 15D predictors were identified with OLS 
regression and subsequently controlled for with ANCOVA. The presence of coronary heart 
disease resulted in significant utility decrements for all instruments, while diabetic 
retinopathy only significantly decreased the 15D utilities. After controlling for a set of 
confounding variables 15D still discriminated between diabetes with and without coronary 
heart disease (seven dimensions) affected and diabetic retinopathy (five dimensions 
affected). The authors explain this finding with the richer descriptive system of the 15D. 
The authors suggest the findings may be evidence for preferring the 15D in economic 
evaluations of interventions for diabetes. 
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Among the three studies using 15D only, two included type 1 diabetes patients 
(52;53) and one study included type 2 diabetes patients (same as the last study regarding 
SF-6D, described above). 
The aim of a Finnish study (52), which used the 15D instrument on 1,023 patients 
with type 1 diabetes, was to assess HRQoL and its association with diabetic complications 
in a sample of individuals with type 1 diabetes. The participants were from a large study 
namedthe Finnish Diabetic Nephropathy study. The mean 15D score was 0.899.  No 
difference between men and women was observed. HRQoL decreased with increasing age 
among patients with and without diabetic complications. By means of a Tobit regression 
model, reduction in HRQoL was explained by macroalbuminuria, dialysis, renal transplant, 
poor glycemic control, aging and longer diabetes duration with utility decrements of -
0.036, -0.082, -0.053, -0.006, -0.002 and -0.001, respectively. Nephropathy affected all but 
five dimensions of the individual dimensions of 15D. Retinopathy affected vision, 
mobility, eating and usual activities. The authors conclude that the 15D scores decreased 
with increasing age. Reduced HRQoL was observed in persons with nephropathy. This was 
not the case for retinopathy.  
A second study from Finland (53), with type 1 diabetes subjects, aimed to measure 
the impact of symptoms of diabetes-related long-term complications on HRQoL. 
Individuals were collected at random from the drug reimbursement registry of the Social 
Insurance Institution in Finland. 592 were included in the study as they met the inclusion 
criteria. Collection of data was done by a postal questionnaire with questions regarding 
symptoms, diagnoses and treatments indicating time of appearance and presence of long-
term complications such as retinopathy, nephropathy, neuropathy, macrovascular 
complications (problems in arterial circulation and coronary heart disease) and stroke. Data 
on HRQoL were collected with the 15D. In order to estimate the effects of symptoms of 
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complications on HRQoL and to separate these effects from effects of other health 
problems and aging, the authors constructed a Tobit model. A markedly decline in 15D 
scores was observed with increasing age, and when the prevalence of symptoms of long-
term complications increased. The Tobit regression model showed that these symptoms 
have a significant negative influence on HRQoL. The authors conclude that the high 
prevalence of symptoms of long-term complications combined with their significant 
negative influence on HRQoL causes substantial losses in terms of quality of life and utility 
from both individual and societal perspectives. Furthermore they conclude with 
emphasizing the importance of secondary prevention (prevention of complications by 
better metabolic control). 
With few exceptions, little has been done in Norway to study quality of life among 
individuals with diabetes (54;55). In order to get an overview of research on quality of life 
and diabetes a broad search in PubMed with the search string “quality of life AND diabetes 
AND Norway” (search per 06.05.12) was conducted. Criteria for inclusion were: either 
15D, SF-6D or EQ-5D was the instrument used in the study, study of HRQoL of diabetes 
(type 1, type 2 or both types) was the aim of the study, and lastly that the study was 
performed in the Norwegian setting. This search returned 50 titles. The only study that met 
the criteria for inclusion was Paper II of this thesis. The rest of the studies were either: 
performed in other countries, not studying diabetes (for example a series of studies on 
HRQoL related to diabetic foot ulcers) or utilizing disease-specific tools for measuring 
HRQoL.  
 
8.3. Cost-effectiveness – diabetes – lifestyle interventions 
Searching PubMed with the search-terms “diabetes” and “cost-effectiveness” returned 
1,070 references, while the number is down to 357 if “diabetes” is replaced by “type 2 
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diabetes” (search performed 06.05.12). In order to increase the relevance of the search to 
the scope of this thesis we searched PubMed with the search terms “"Cost-Benefit 
Analysis"[Mesh] AND diabetes AND lifestyle. Criteria for inclusion were that a lifestyle 
intervention was studied, a cost-effectiveness analysis was conducted, that it was related to 
prevention or progression of type 2 diabetes, and that a simulation model was utilized. 
Studies related to screening for diabetes were excluded. The search returned 114 articles, 
among which 96 were excluded after reading the title and further ten were excluded after 
reading the abstract. This left us with eight studies of interest.  
A Swedish study (56) investigates the cost-effectiveness of the Stockholm Diabetes 
Prevention Program, a community-based program during 1995 to 2004 in three 
municipalities, aiming to promote healthy lifestyles to prevent type 2 diabetes. The 
program focused on the preventable risk factors for type 2 diabetes (physical inactivity, 
poor dietary habits, obesity, and tobacco use, by means of both individual lifestyle and 
community change). The program seems less fixed and strict, with a main strategy of 
community organization and participation to develop community relations, and to educate 
and implement activities with local organizations. Effectiveness was measured in terms of 
risk factor levels in a population group aged 36-56 years at baseline and 8-10 years later 
(2,149 men; 3,092 women). Program municipalities were compared with a control area. 
With a Markov model future diabetes and cardiovascular disease-related health effects and 
societal costs were estimated in a cost-utility analysis. The study reports conflicting results 
regarding the cost-effectiveness of the program. The author still claims, due to the results 
from two study groups, that community-based lifestyle-programs aiming to prevent 
prediabetes and diabetes might be cost-effective. 
The aim of a Dutch study (57) was to investigate the potential long-term health and 
economic consequences of lifestyle interventions for diabetic patients. Using a Markov 
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model (the Chronic Diseases Model), with a lifelong time horizon, the authors explored the 
health benefits and cost-effectiveness for these interventions when implemented in the 
Dutch diabetic population. The average gain in QALYS per participant ranged from 0.01 to 
0.14. The costs were deemed to be reasonable being equal to or less than €50,000 per 
QALY. A self-management education program and physical activity counselling achieved 
the best results with a high probability of being very cost-effective with cost per QALY 
being equal to or lower than €20,000. The authors conclude that implementation of lifestyle 
interventions is likely to give important health benefits at reasonable costs, but the evidence 
for long-term maintenance of health benefits is limited.  
The Finnish Diabetes Prevention Study was a randomized intervention program that 
evaluated the effect of intensive lifestyle modification on the development of diabetes 
mellitus type 2 in patients with impaired glucose tolerance. A 2007 study (58) utilized data 
from this study to explore whether such interventions are good value for money. A 
simulation model was designed to address the economic consequences of the intervention 
applied in a Swedish setting. Data from the trial were used to assess the effect of 
intervention on the risk of diabetes and on risk factors for cardiovascular disease. Risk of 
cardiovascular disease and stroke was estimated with the means of results from the United 
Kingdom Prospective Diabetes Study. Cost data were taken from Swedish studies. With a 
healthcare payer perspective, the model found the program to be cost-saving. The estimated 
increase in life years was 0.18. Cost-effectiveness ratio was €2,363 per QALY gained. The 
authors conclude that the lifestyle intervention directed toward high-risk subjects would be 
cost-saving for the healthcare payer and highly cost-effective for society as a whole. 
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In a Canadian study of individuals with impaired glucose tolerance (59), the authors 
aimed to compare the health and economic outcomes of acarbose3, an intensive lifestyle 
modification program, metformin or no intervention, all used to prevent progression to 
diabetes. A Markov model was developed with four main states: impaired glucose 
tolerance, diabetes, normal glucose tolerance and death. Results from the Diabetes 
Prevention Study (mentioned above) and the Diabetes Prevention Program (to be described 
below) were utilized. Both of these were studies related to diabetes and lifestyle 
modification. These studies were used to estimate the impact of each intervention on 
transition rates between states. The results indicate that the treatment cost-effective way to 
prevent diabetes and may generate cost savings. Treatment with medicines tended to be 
less costly. Intensive lifestyle modification, if maintained, led to the greatest health benefits 
at reasonable incremental costs. 
The Diabetes Prevention Program (DPP) (60) was a 27-center randomized clinical 
trial to determine whether lifestyle intervention or pharmacological therapy (metformin) 
would prevent or delay the onset of diabetes in individuals with impaired glucose tolerance 
(IGT), that were at high risk of disease. The study comprised 3,234 participants who were 
randomized to one of three study-arms, with 1,079 randomized to lifestyle intervention. 
The DPP lifestyle intervention was based on empirical literature in nutrition, exercise, and 
behavioural weight control, especially as it applied to the prevention of type 2 diabetes in 
diverse ethnic groups. The lifestyle intervention proved to be successful with a 58% 
reduction in the incidence rate of diabetes. Several studies have utilized data from the DPP 
study. Some of these are described below. 
A study from 2005 (61) aimed to estimate the lifetime cost-utility of the DPP 
interventions with the means of a Markov simulation model used to estimate progression of 
                                                 
 
3 According to the Norwegian Prescription Database there were 701 users of acarbose (Glucobay) in Norway 
in 2011. 
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disease, costs, and quality of life. The lifestyle and metformin interventions compared with 
the placebo intervention were estimated to delay the development of type 2 diabetes by 11 
and 3 years, reduce the absolute incidence of diabetes by 20% and 8% and improve 
survival with 0.5 and 0.2 years, respectively. The cost per QALY was approximately 1,100 
USD for the lifestyle intervention and 31,300 USD for the metformin intervention, 
compared with the placebo intervention. The interventions were estimated to cost 8,800 
USD and 29,900 USD per QALY, respectively with a societal perspective. The lifestyle 
intervention dominated the metformin intervention with both perspectives. The authors 
conclude that health policy should promote diabetes prevention in high-risk individuals. 
Another DPP-based study (62) reach a similar conclusion but comments that the 
program used in the DPP study may be too expensive for health plans or a national 
program to implement. 
A 2004 DPP- based study (63) aimed to explore whether implementing the active 
treatments used in the DPP would be cost-effective in Australia, France, Germany, 
Switzerland, and the United Kingdom. With probabilities from the DPP and published data, 
and country-specific direct costs a Markov model was employed. The overall finding is that 
the DPP interventions could lead to an increase in diabetes-free years of life, improvements 
in life expectancy, and either cost savings or minor increases in costs compared with 
standard lifestyle advice in a population with impaired glucose tolerance. The conclusion 
draw is that financial constraints should not prevent the implementation of diabetes 
prevention programs. 
In a 2003 study (64) aimed to assess (within the DPP trial) the cost-effectiveness of 
the lifestyle and metformin interventions relative to the placebo intervention. Again, top-
line of the findings in the study was that the lifestyle and metformin interventions were 
effective and were cost-effective from the perspective of a health system and society (over 
48 
 
 
three years). The authors conclude that both interventions are likely to be affordable in 
routine clinical practice, especially if implemented in a group format and with generic 
medication pricing. 
No studies similar to the study conducted in Paper III of this thesis were identified. 
The studies described above are different from Paper III in a number of ways. None of the 
studies investigated lifestyle-intervention related to progression of established type 2 
diabetes and the avoided or delayed administration of insulin. One of the studies above was 
lifestyle intervention applied at a community level promoting lifestyle changes in the 
general population. The rest of the studies were mainly investigating the progression from 
impaired glucose tolerance to diabetes, or earlier stages of diabetes. The differences 
described above may explain differing results from the findings in our Paper III.  
In Norway cost-effectiveness analyses have been performed mostly by the 
pharmaceutical industry in relation to reimbursement applications for medicines4. In 
Norway these applications are considered confidential, but an evaluation report from the 
Norwegian Medicines Agency is made public, sometimes with sections blacked out for 
confidentiality reasons. However in many cases when cost-effectiveness analyses are 
performed in Norway, they are based on input and data from other countries. A search in 
PubMed with the search terms "Cost-Benefit Analysis"[Mesh] AND diabetes AND 
Norway” show that little research is done in Norway. The search returned only nine 
studies, of which none are relevant to the scope of this thesis. Data specific for Norway 
should be used in economic evaluation or to provide information on the transferability of 
data from other countries. 
 
 
                                                 
 
4 www.slv.no/upload/139120/refusjonsrapport_levemir_mars2010.pdf 
www.slv.no/upload/126455/refusjonsrapport_januvia_sept09.pdf 
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9. RESEARCH QUESTIONS 
 
 
Paper I  
The aim of this study was to estimate the health care costs attributable to type 1 and type 2 
diabetes in Norway in 2005. 
 
Paper II  
The aim of this study was to describe how diabetes complications influence the health-
related quality of life of individuals with diabetes using the individual EQ-5D dimensions 
and the EQ-5D index.  
 
Paper III  
The aim of this study was to estimate the (quality adjusted) life year gains and lifetime 
costs of two-year, five-year and lifelong lifestyle intervention compared to immediate 
switch to insulin in patients with poorly controlled type 2 diabetes. 
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10. MATERIALS AND METHODS 
In the Cost-of illness study we set out with a desire to report results for type 1 and type 2 
diabetes separately. During the data collection it became apparent that many of the data 
sources did not separate between the two types of diabetes. We therefore reported results 
separately as much as possible, and aggregated when this was not possible. In the HRQoL-
study we relied on the self-reported diabetes type collected from the questionnaire. In the 
cost-effectiveness study the clinical input data were on individuals with type 2 diabetes. 
Data on costs and HRQoL were assigned accordingly. 
 
10.1. Cost-of illness study input data 
In order to capture costs related to diabetes we collected data from a range of different 
institutions and databases. To fill in the gaps of information not readily available we 
conducted a survey in a group of individuals with diabetes. The table below show the 
sources of cost data we used in the COI analysis. 
 
Table 1 Data-sources used in the Cost-of illness study  
 Cost factor Source of data 
Direct costs In hospital care NPR* 
 Out-patient care NLWA** 
 GP and emergency visits NLWA 
 Private practicing specialist services NLWA 
 Insulin and analogues (A10A***) NorPD**** 
 Oral glucose lowering drugs (A10B***) NorPD 
 Cholesterol lowering drugs  SURVEY/NLWA 
 Antihypertensive drugs SURVEY/NLWA 
 Medical devices NLWA 
 Nutritionist guidance  SURVEY 
 Foot therapist SURVEY 
 Physiotherapy SURVEY 
 Acupuncture SURVEY 
Indirect costs Sickness compensation NLWA 
 Permanent disability pension and time limited disability 
pension   
NLWA 
 Basic and/or supplemental benefits NLWA 
 
*  Norwegian patient register   ** The Norwegian Labour and Welfare Administration *** ATC code **** 
The Norwegian Prescription Database   **** Survey of diabetes in Norway 2006 
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10.1.1. Survey of diabetes in Norway 2006 
Data collection 
For various other types of resource use where register data are not available, we obtained 
information through a self-administered questionnaire. We developed a comprehensive 
questionnaire (see appendix 1) in collaboration with patients and doctors with diabetes care 
experience. The questionnaire was designed for optical scanning and capturing of data. The 
questionnaire was piloted twice, first among a selection of health care professionals 
employed in government and the pharmaceutical industry and secondly among county 
leaders in the Norwegian Diabetes Association (NDA).   
In order to recruit persons with diabetes to a survey the possibilities are limited. 
However persons with diabetes have a Norwegian organization, (NDA). Membership in 
voluntary and the objective of the NDA is to promote diabetes related issues and maintain 
the interests of persons with diabetes in Norway. A large proportion of persons with type 1 
diabetes in Norway are members of the NDA while only a minority of those with type 2 
diabetes (about 15,000) are members, and some members are individuals with an interest in 
diabetes. After excluding persons under the age of 18 and non-diabetes individuals (health 
care workers and others with an interest in diabetes) NDA drew a random sample of 1,000 
members from the membership file of NDA (36,000 members in 2006).  
The questionnaire was mailed to the sample patients in May 2007. The respondents 
were asked to state their use of the following types of health care services for the previous 
three months: physiotherapy, acupuncture, nutrition counselling and GP home visits for 
hypoglycaemia. They were also asked questions about duration of the diabetes, type of 
treatment and occurrence of diabetic related complications. Non-respondents were 
followed up twice. The last follow up was accompanied by a letter written by the NDA, 
encouraging the participants to respond to the survey.  When the survey was ended, we sent 
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all responses to a company specializing in optical scanning and capture of data. We 
performed a manual check of the data file we received after the optical scanning. This 
revealed a large number of inaccuracies and we had to perform a manual check of all 
questionnaires and manually correct the data file. 
The questionnaire was approved by Regional Committee for Ethical Research and 
Norwegian Social Science Data Services.  
 
Responders and non responders 
Of the total 1,000 individuals with diabetes, 19 were excluded because they had died (n=4), 
had unknown address (n=13) or declined to participate (n=2). In total 598 of the eligible 
patients (61%) returned the questionnaire, of which 521 were complete and could be used 
in further analysis. Among non-respondents, 51% were female (based on first name) 
compared with 47% among respondents.  
Among the 521 respondents, 165 were of type 1 diabetes (53% females), and 356 
had type 2 diabetes (44% females). Mean duration of diabetes was 22 and 10 years, body 
mass index was 25.8 and 28.9, for type 1 and type 2 diabetes, respectively. With few 
exceptions the type 1 group reports using insulin and the type 2 group reports oral 
antidiabetic medicines. In the type 1 diabetes group 33% stated that they used 
antihypertensives and 28% cholesterol lowering drugs. The respective figures in the type 2 
groups were 63% and 59%. More details and further descriptive statistics about 
demographics, risk factors for complications, medication and complications are shown in 
table 1, Paper II.  
The only information we could obtain on non-responders was gender. We registered 
and counted the first names of all non-responders and found there was little discrepancy. 
 
53 
 
 
10.1.2. Data from the Norwegian Patient Register 
A broad range of diabetes diagnose-codes were requested from the Norwegian Patient 
Register (NPR). The aim was to explore the use of diabetes-related diagnose-codes. We 
obtained information on all hospital stays with the following ICD-10 codes as main or 
secondary diagnosis5: E10, E11, E23.2, H28.0, N08.3, O24, P70.0, P70.1, P70.2, R73.0 
and Z13.1. The codes P70.0, P70.1 (both gestational diabetes), P73.0 (pre-diabetes) and 
Z13.1 (encounter for screening for diabetes mellitus) accounted for a small fraction of the 
dataset (as main diagnosis, 175, 0 and 5 observations, respectively). The impact of these 
admission codes was deemed to be very small and we kept them in the further analyses for 
the purpose of covering a broad range of diabetes related codes. For each stay we obtained 
anonymous data on the primary diagnosis, secondary diagnoses, age, gender, geographic 
location, length of stay and DRG-weight. In Norway, hospital services are provided by five 
Health regional health authorities, each with an independent board. Geographic variation 
was analysed according to these five regions.  
 
10.1.3. Data from NLWA 
Out-patient clinic visits 
Using the same ICD-10 codes as for in-patient services, data on the costs of out-patient 
clinic visits were provided by The Norwegian Labour and Welfare Administration 
(NLWA). No data for 2005 were available so data for 2006 were used. The NLWA data 
encompasses government reimbursements to hospitals. We added the standard patient co-
payment per visit (NOK260). According to the financing model for hospitals, 
                                                 
 
5 E10 (insulin dependent diabetes mellitus), E11 (non-insulin dependent diabetes mellitus), E23.2 (diabetes 
insipidus), H28.0 (diabetic cataract), N08.3 (glomerular disorders in diabetes mellitus), O24 (diabetes 
mellitus in pregnancy), P70.0 (syndrome of infant of mother with gestational diabetes), P70.1 (syndrome of 
infant of a diabetic mother), P70.2 (neonatal diabetes mellitus), R73.0 (abnormal glucose tolerance test) and 
Z13.1 (special screening examination for diabetes mellitus). 
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reimbursements and co-payments encompass 40% of the estimated out-patient clinic costs. 
The sum was therefore adjusted upwards by a factor of 2.5.  
 
Physician services 
Data on the use of general practitioner (GP) services and private specialists were obtained 
from NLWA. Claim forms, 90% of which are delivered electronically to NLWA, are 
provided with ICPC codes. We obtained data on all visits with ICPC codes T89 (insulin 
dependent) and T90 (non-insulin dependent) diabetes. For each patient contact, we 
obtained data on diagnosis, type of contact, reimbursement and patient co-payment.  
 
Medical equipment 
The NLWA keeps account of reimbursement for diabetes self-tests and insulin injection 
equipment (injection catheters, insulin pens and needles, syringes, lancets for blood 
sampling). To avoid double counting, the costs of insulin pumps were excluded. Insulin 
pumps are administered in hospitals and costs are captured in the DRG costing system. 
 
Indirect costs 
Sickness compensation, permanent disability pension, time limited disability pension, and 
basic and/or supplemental benefits, are funded by the NLWA. We obtained data on all 
payments in 2005 for the ICD-10 diagnoses: E10, E11, E23.2, H28.0, H36.0, N08.3, O24, 
P70.0, P70.1, P70.2, R73.0 and Z13.1. A search was performed with all equivalent ICD-9 
codes as well. Furthermore, the following ICPC codes were included6: T89, T90, W85 and 
F83.   
 
                                                 
 
6 T89 (insulin dependent diabetes mellitus), T90 (non insulin dependent diabetes mellitus), W85 (diabetes 
during pregnancy) and F83 (retinopathy). 
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10.1.4. Data from Norwegian Prescription Database 
The Norwegian Prescription Database (NorPD) contains information on all prescriptions 
redeemed from pharmacies. We obtained data for 2005 on the following categories of ATC 
codes: A10A (insulin and analogues) and A10B (glucose lowering drugs). Additionally, we 
included the costs of patient reported use of antihypertensive drugs and cholesterol 
lowering drugs according to the findings in our survey. Data on the use of antihypertensive 
drugs and cholesterol lowering drugs were collected in the survey and a weighted average 
price per dose was calculated based on sales figures from 2005 collected from the NorPD.     
 
10.1.5. Use of public registries in research 
The cost-of illness analysis relies heavily on data from available data registers for the 
Norwegian health care system and The Norwegian Labour and Welfare Administration 
(NLWA). One major advantage of use of register data is that they encompass the total 
population and therefore in principle provides data on the total use of different types of 
health care. The use of registers should in principle reduce selection bias. Use of register 
data may have considerable limitations in terms of quality, however.  Doctors and others 
who provide the data may be busy and less motivated to provide correct data. This may 
apply not least to diagnoses and procedures that influence cost estimates. Here, use of 
diagnosis impact funding of the hospitals, and hospitals may consider using inaccurate 
diagnosis to increase reimbursements. Some registers such as the Norwegian Prescription 
Database (NorPD) are likely to have very accurate data because they are based on 
redeemed prescriptions. Possible limitations of the NorPD are lacking registration of over-
the-counter medicines, and incorrect or lacking personal identification numbers. The 
NLWA registers may be accurate in terms of actual costs, but the diagnoses may be 
inaccurate.  
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An alternative methodological approach would have been to collect high quality 
data for groups of patients and extrapolate to the total population. This however introduces 
uncertainty of the representativeness of the extrapolated sample. 
 
10.2. Quality of life study inputs 
Our HRQoL data stem from the survey described in section 10.1.1. The EQ-5D responses 
were translated into EQ-5D index utilities using the UK TTO tariff (25;65). 
 For descriptive statistics, we used means, proportions and standard deviations. 
Groups were compared using Fisher’s exact test or the t-test. Determinants of EQ-5D 
dimension values were analysed by logistic regression. Because none of the respondents 
indicated level 3 (“extreme problem”) for MOBILITY and SELF-CARE, we applied binary 
logistic regression to analyse these dimensions. For the dimensions USUAL ACTIVITIES, 
PAIN/DISCOMFORT and ANXIETY/DEPRESSION all three levels of severity were 
present and ordinal logistic regression could be used. The assumption of proportional odds 
was met when the two types of diabetes was analysed together, as assessed with a Brant 
test. Additional analysis, however, showed that the independent variables had differing 
impact on the dependant variable for the two types of diabetes. The proportional odds 
assumption was not met when type 1 and type 2 diabetes were analysed separately. 
Consequently, we performed separate binary logistic regressions for type 1 and type 2 
diabetes and merged level 2 and 3 on the EQ-5D dimensions.  
 For the analysis of the EQ-5D index a number of regression models were 
considered. In order to obtain coefficients directly interpretable as decrease in HRQoL 
value we used a linear OLS regression model. The Breusch-Pagan test and plotting 
residuals versus fitted values showed that heteroskedasticity was present both for type 1 
and type 2 diabetes. Therefore, we applied White’s robust variance estimators.  
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 The data were complete except for the covariates “Fear of hypoglycaemia” (13% 
missing), “Limitations at work” (23% missing) and “Limitations socially” (10% missing). 
Missing values were therefore imputed with regressions based on 15 independent variables 
(sex, age, weight, height and 11 diabetes-related complications). We used the impute 
function in STATA, which runs regressions by simple best-subset linear regression, 
looking at the pattern of missing values in the predictors. 
 We tested the covariates age and body mass index first as dummy variables divided 
in quartiles and second as continuous variables. 
 We chose covariates for the models based on input from health care professionals 
and knowledge of the disease. The aim was to choose covariates that could be associated 
with the dimension in question (example: amputation – MOBILITY and Neuropathy – 
PAIN/DISCOMFORT).  In the binary regressions, we initially started with a full model and 
manually omitted variables one by one such that only statistically significant covariates 
were retained. The results from this approach can be seen in tables 6 and 7 (for the 
respective diabetes types) in the results section, and was chosen to identify the covariates 
with the greatest impact on each dimension. This approach was later, in a review process 
changed to retaining all covariates throughout the analysis, regardless of whether they were 
significant or not (see table 4 and 5, Paper II). 
 In the linear regression a full set of covariates was kept throughout the analysis in 
order to provide a full set of variables with both significant and non-significant impact on 
the covariates. The latter was done to provide a full set of results which may be used by 
other analysts in decision analytic modelling. All analyses were performed in STATA/SE 
10.0 (Stata Corp, College Station, TX, USA). 
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10.3. Cost-effectiveness analysis of a lifestyle intervention versus insulin 
10.3.1. Clinical data from the Aas et al. study  
In the Aas study (66) thirty eight patients were randomized to one of the following 
strategies: 1) lifestyle intervention, 2) lifestyle intervention + insulin treatment and 3) 
insulin treatment alone. The lifestyle intervention consisted of 14 group meetings with 
dietary advice. Furthermore each participant had two individual sessions, focusing on 
advice and goal setting. The exercise programme consisted of group based exercise for one 
hour, twice a week. In addition, patients attended an individual consultation encouraging 
increased activity and energy expenditure. The study intervention lasted for one year. The 
baseline characteristics of all patients and in the randomized subgroups can be seen in 
figure 1, Paper III.  
In total ten of the patients dropped out of the study (four due to illness and six due 
to non-compliance). Patients that did not complete the study did not differ in age or 
duration of diabetes, nor change in weight and HbA1c, during the run-in period. Dropout 
rates were similar in the three treatment groups. 
 The lifestyle intervention group experienced weight loss and a decrease in blood fat 
levels during the intervention year, while the two remaining groups gained weight. Patients 
were checked one year after the end of study with the results showing that the effect had 
disappeared during this time. The clinical data relevant for use in our modelling study can 
be seen in table 1, Paper III. 
 In order to populate the UKPDS Outcomes Model with the patients described in the 
Aas study more information was required. The authors were contacted and asked to provide 
us with data according to the list showed in the table below. 
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Table 2    Clinical data requirements for the UKPDS Outcomes Model 
 
The items that need to be provided for each subject are*: 
ID  Subject identifier (optional) 
Demographic characteristics 
Ethnicity  1=White-Caucasian, 2=Afro-Caribbean, 3=Asian-Indian 
Gender  M=Male, F=Female 
Age  Age in years at diagnosis of diabetes 
Dur  Duration in years since diagnosis of diabetes 
Weight  Weight in kg at diagnosis of diabetes [1.0 Kg = 2.2 pounds] 
Height  Height in meter at diagnosis of diab [1.0 metre = 39 inches] 
Risk factor values at diagnosis of type 2 diabetes 
Atrial Fib  Presence of atrial fibrillation (Y=Yes, N=No) 
PVD  Presence of peripheral vascular disease (Y=Yes, N=No) 
Smoking  Smoking status (0=Never, 1=Past, 2=Current) 
Chol  Total cholesterol (mmol/l) [1.0 mmol/l = 38.6 mg/dl] 
HDL  HDL cholesterol (mmol/l) [1.0 mmol/l = 38.6 mg/dl] 
SysBP  Systolic blood pressure (mm Hg) 
HbA1c  HbA1c (%) 
Current risk factor values (leave blank if data not available) 
Smoking  Smoking status (0=Never, 1=Past, 2=Current) 
Chol  Total cholesterol (mmol/l) [1.0 mmol/l = 38.6 mg/dl] 
HDL  HDL cholesterol (mmol/l) [1.0 mmol/l = 38.6 mg/dl] 
SysBP  Systolic blood pressure (mm Hg) 
HbA1c  HbA1c (%) 
*  Full definitions of the input variables used are given in UKPDS 68. 
 
We lacked data on characteristics of the patients at the time of diagnosis, however. 
In order to obtain these values we made the assumption that the patient had the same 
HbA1c values at diagnosis as at the start of the study. This was based on the assumption 
that at both these points in time patients have contact with the Health care system due to 
lacking blood sugar control. 
 
10.3.2. The UKPDS Outcomes Model 
Ideally we would have developed a Norwegian diabetes model, totally representative of the 
Norwegian diabetes population, with all epidemiological, cost and quality of life values 
collected and derived in Norway. Unfortunately, most of the necessary data, not least the 
epidemiological ones, are not available for Norway. Also, the development of such a model 
was beyond the time resources of this PhD project. We therefore chose to adopt a model 
developed elsewhere. A number of models have been developed and could potentially be 
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used (67-69). The choice of model was discussed with health economists with experience 
with diabetes modelling in other countries, and they recommended the UKPDS Outcomes 
Model. We therefore chose to use the UKPDS Outcomes Model because of its availability, 
because it is based on a large UK observational study and because it only requires standard 
software (EXCEL).  
At the time the UKPDS Outcomes Model was developed a number of models were 
already available. However, the authors presenting the UKPDS Outcomes Model (23) 
found that there were major limitations to most of the models. For instance one of the 
models present at the time utilized data from a type 1 diabetes trial, and derived its 
cardiovascular risk estimates from the Framingham cohort study (70). This was a major 
weakness because the Framingham study only encompassed 337 patients with type 2 
diabetes. This could mean that the basis for cardiovascular risk in the model could be 
inaccurate. 
The United Kingdom Prospective Diabetes Study (UKPDS) (71) was a multi-
centre, prospective, randomized, intervention trial of 5,100 newly-diagnosed patients with 
type 2 diabetes, the largest clinical research study on diabetes ever conducted at the time. 
The study aimed to determine whether improved blood glucose control could prevent 
complications and reduce the associated morbidity and mortality. The UKPDS did provide 
evidence that the serious complications related to type 2 diabetes can be significantly 
reduced by appropriate treatment. The UKPDS resulted in a range of publications, and is 
frequently cited. Utilizing data from the UKPDS study became a well validated data source 
of diabetes-specific data. A search for “UKPDS” in PubMed returns 456 papers.  
The UKPDS Outcomes Model (23) is based on data from the above mentioned 
United Kingdom Prospective Study (UKPDS).  The aim of the study presenting the 
UKPDS Outcomes Model was to develop a simulation model for type 2 diabetes that could 
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be used to estimate the likely occurrence of major diabetes-related complications over a 
lifetime. This could in turn be used to calculate health economic outcomes such as quality-
adjusted life expectancy (QALE). The UKPDS Outcomes Model is a large integrated 
system of equations used to forecast major diabetes related complications. The simulations 
are based on a probabilistic discrete-time illness–death model. The cycle length is one year. 
When running the model the patients start with a given health state, for instance a certain 
set of parameter values and no complications. In any model cycle the patients may have 
one or more non-fatal complications and/or may die. The UKPDS Outcomes Model is 
based upon 14 risk equations (see appendix 5-7). All equations are survival functions 
derived from UKPDS. Seven of the equations are event functions, each describing the 
probability of experiencing a diabetes related event/complication (MI, IHD, CHF, renal 
failure, blindness, amputation and stroke). Three of the equations are mortality functions. 
One describes the probability of a diabetes related event being fatal, one the probability of 
death for a person with diabetes and the last one death from other causes. The four last 
equations are risk functions relating to how different clinical parameters influence the 
probability of death (HbA1c, SBP, HDL and smoking). 
The UKPDS Outcomes Model enables estimation of confidence intervals for 
estimates of Life Expectancy, Quality Adjusted Life Expectancy and complication costs. 
The following is stated about this in the UKPDS Outcomes Model manual:   
“The software contains full sets of model equation parameters derived from bootstrap 
samples of the UKPDS trial population which were generated by sampling with 
replacement from the original data set. When the desired number of bootstraps has been 
chosen, each bootstrap run will use a different set of model equation parameters, drawing 
from those available. The current version of the software is limited to a maximum of 1,000 
bootstraps. Ideally 1,000 bootstraps should be specified although 100 may be sufficient to 
62 
 
 
obtain approximate confidence intervals estimates”. We used this function and chose 100 
bootstraps, this enabled us to produce confidence intervals.  Using more than 100 
bootstraps caused EXCEL to freeze up for unknown reasons.  
 
10.3.3. Unit costs and HRQoL data 
Unit costs are an important input in modelling and vary across countries. In order to adapt 
the UKPDS Outcomes Model to the Norwegian setting we sought to use Norwegian 
specific cost data to the furthest extent. Some costs were derived from the physicians fee 
schedules and DRGs and finally some cost data are from the NORCAD manual (72). 
In the table below the default costs and utility decrements in the UKPDS Outcomes 
Model are shown alongside our best estimates of the same in the Norwegian setting. The 
default UKPDS Outcomes Model costs (shown in the top-part of the table below) are 
converted from English pounds to Norwegian Kroner (NOK) using an exchange rate of 10. 
The utility decrements associated with a complication are mostly similar in both tables, but 
the initial utility value was set to another level based on findings in our own HRQoL study 
(Paper II).   
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Table 3    Unit costs (in our adaptation: 2009* costs (NOK)) and utility decrements (top part of table - 
default in the UKPDS Outcomes Model, bottom part of table - used in our adaptation)    
   
 
DEFAULT IN THE UKPDS OUTCOMES MODEL 
 
Initial utility: 0.785** 
 At time of event In subsequent years 
 Fatal Non-fatal Utility decrement** Cost 
Utility 
decrement** 
Ischemic heart disease (IHD)  26 960 -0.090 8 910 -0.090 
Myocardial infarction (MI) 13 660 51 990 -0.055 8 560 -0.055 
Heart failure  30 070 30 070 -0.108 10 540 -0.108 
Stroke  40 110 31 800 -0.164 6 010 -0.164 
Amputation  103 540 103 540 -0.280 5 980 -0.280 
Blindness   13 580 -0.074 5 750 -0.074 
Renal failure  300 000 300 000 -0.263 300 000 -0.263 
 
USED IN OUR ADAPTATION OF THE UKPDS MODEL 
 
Initial utility: 0.850a
Ischemic heart disease (IHD)  83 240b -0.090c 4 390b -0.090c 
Myocardial infarction (MI) 42 749b 101 234b -0.055c 3 509d -0.055c 
Heart failure  29 596b 29 596b -0.108c 27 094b -0.108c 
Stroke  180 000b 180 000b -0.164c 84 297e -0.164c 
Amputation  113 390f 113 390f -0.280c 95 000g -0.280c 
Blindness   69 425h -0.074c 889i -0.074c 
Renal failure  49 461j 577 382k -0.263l 577 382k -0.263l 
 
* Some cost elements (fees) are from 2008. This is considered to make no noticeable impact on results  
**The UKPDS Outcomes Model assume that utility value decrements for multiple co-morbidities are additive 
(example: the utility of a patient who had other IHD and then had an MI would first be decremented by 0.090 
and then by a further 0.055). The utility decrements are permanent, lasting for the remaining life years. 
a Solli O, Stavem K, Kristiansen IS: Health-related quality of life in diabetes: The associations of 
complications with EQ-5D scores. Health Qual. Life Outcomes 8:18, 2010 
b Wisløff T, Selmer RM, Halvorsen S, and Kristiansen IS. Norwegian Cardiovascular Disease Model 
(NorCaD) – a simulation model for estimating health benefits and cost consequences of cardiovascular 
interventions.  2008. Oslo 
c Default in the UKPDS Outcomes Model. Source: Clarke P., Gray A. & Holman R. Estimating utility values 
for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) Medical Decision Making (2002); 
22: 340-349 
d Assumption: Per year: 4 GP visits (NOK289 per visit, source: Fee Schedule for GP’s), lipid and enzyme 
tests at each visit (NOK212 per test, source Fee Schedule for GP’s) and assumed usage of statins, 
antihypertensives and acetylsalicylic acid.      
e Adapted from Fjærtoft H, Indredavik B, Magnussen J et al. Early supported discharge for stroke patients 
improves clinical outcome. Does it also reduce use of health services and costs? Cerebrovasc Dis 2005; 19: 
376 - 83. 
f DRG113 
g Tennvall GR, Apelqvist J, Eneroth M.: Costs of deep foot infections in patients with diabetes mellitus. 
Pharmacoeconomics. 2000 Sep;18(3):225-38. 
h Assumption: One hospital admission for eye disease (DRG46+47, NOK19,347), two  follow-up visits with 
ophthalmologist (NOK889 per visit, source Specialist Fee Schedule) and 0.5 information/course for patients 
with blindness in one eye (NOK2,300 per day, assumed length 42 days). 
i Assumption: Per year, one specialist consultation (NOK889 per visit, source Specialist Fee Schedule) 
j DRG 317 
k DRG 316x3x52 
l Default in the UKPDS Outcomes Model. Source: Kiberd BA & Jindal KK. Screening to prevent renal failure 
in insulin dependent diabetic patients: an economic evaluation BMJ 1995; 311 (702) 1595-1599 
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 The UKPDS Outcomes Model estimates the risk of complications and the 
associated costs and utility decrements. The model does not capture the cost of treating 
diabetes (insulin, oral glucose lowering drugs, diabetes equipment, etc) or diabetes related 
costs (nutrion counselling, lifestyle interventions, etc.). We captured such costs in a 
separate EXCEL spreadsheet model, alongside the UKPDS Outcomes Model. Our 
estimated cost data from this spreadsheet are shown in the table below. 
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Table 4     Estimated costs of insulin, oral glucose lowering drugs, diabetes equipment and the lifestyle 
intervention (2009) Norwegian Kroner (NOK) 
 
Cost type 
 
Per patient per year (NOK)* 
DIRECT COSTS  
Insulin (excl. VAT) 5 300** 
Equipment associated with insulin use 7 234*** 
Oral glucose lowering drugs (excl. VAT) 908** 
GP visits and checkups 1 542 
Overhead Lifestyle intervention  
Medical doctor monitoring 389 
Invitations/information 1 111 
Lifestyle intervention – diet   
Nutritionist guidance group meetings 2 302 
Nutritionist guidance individual session 2 960 
Transportation to sessions and meetings 640 
Lifestyle intervention – exercise   
Trainer/Coach 3 733 
Transportation to exercise 3 200 
Subtotal direct costs 29 319 
 
INDIRECT COSTS (loss of leisure or working hours)  
Lifestyle intervention – diet  
Nutritionist guidance group meetings 17 640 
Nutritionist guidance individual session 2 520 
Lifestyle intervention – exercise  
Exercise sessions 100 800 
Subtotal indirect costs 120 960 
 
Total costs (direct + indirect) year 1 150 279 
Total costs (direct + indirect) year 2**** 148 779 
 
Total costs (direct) year 1 29 319 
Total costs (direct) year 2**** 27 819 
 
*   9 patients in the lifestyle program 
** Based on numbers from 2008. Numbers from 2009 were not available at the time.   
*** Based on numbers from 2005. Numbers from 2005 were collected for Paper I.  
**** Undiscounted 
 
The numbers in the table above are based on information in the Aas study and 
assumptions about the costs of the lifestyle program. Costs of medicines and medical 
equipment were taken from different years available at the time. Calculations and 
assumptions of costs in the table above are shown in the table below. 
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Table 5     Assumptions and calculations - costs of insulin, oral glucose lowering drugs, diabetes 
equipment and the lifestyle intervention (costs shown in table 4) 
 
Cost type Source Calculation 
DIRECT COSTS 
Insulin (excl. VAT) NorPD* Total sale of ATC A10A/Number of users in 2008, multiplied with 0.8 to 
remove VAT – ((337,688,416/50,971)*0.8) 
Equipment associated with insulin use NLWA**, 
NorPD* 
Total expenditure on diabetes equipment (reimbursement and patient co-
payment)/ Number of users of insulin in 2005 - (340,516,405/47,074) 
Oral glucose lowering drugs (excl. 
VAT) 
NorPD* Total sale of ATC A10B/Number of users in 2008, multiplied with 0.8 to 
remove VAT – ((119,398,952/105,192)*0.8) 
GP visits and checkups Assumptions Assume 3 GP-visits per year, cost per GP-visit NOK300,-, assume: 1 
creatinine, 1 HbA1c, 1 cholesterol, test per visit at NOK50,-, NOK50,-, 
NOK114,-, respectively – (300 + 50 + 50 + 114 = 514), (514 x 3 = 1,542) 
Overhead Lifestyle intervention 
Medical doctor monitoring Assumptions Medical Doctor salary per hour NOK500,-, multiplied by 1.4 to include 
social costs, 5 hours in total for the lifestyle programme = NOK3,500,-.  
9 patients. Cost per patient: NOK389,-. 
Invitations/information Assumptions Assume NOK10,000 for the programme. 9 patients. Cost per patient: 
NOK1,111,-. 
Lifestyle intervention – diet 
Nutritionist guidance group meetings Assumptions Assume yearly salary of NOK450,000, multiplied by 1.4 to include social 
costs, 1,700 work hours per year, 14 meetings per year, 4 hours in total for 
preparation and group meetings. Divided by 9 patients. 
Nutritionist guidance individual session Assumptions Assume yearly salary of NOK450,000, multiplied by 1.4 to include social 
costs, 1,700 work hours per year, 2 sessions per year, 4 hours for 
preparation and session.  
Transportation to sessions and meetings Assumptions Assume all meeting/sessions arranged locally and transport is per subway, 
tram or bus. NOK20,- per trip (one way), 14 meetings, 2 sessions. 
Lifestyle intervention – exercise 
Trainer/Coach Assumptions Assume salary per hour NOK300,-, multiplied with 1.4 to include social 
costs. 40 weeks of exercise, 2 sessions per week. Divided by 9 patients. 
Transportation to exercise Assumptions Assume all arranged locally and transport is per subway, tram or bus. 
NOK20,- per trip (one way), 80 exercise sessions. 
  
INDIRECT COSTS (loss of leisure or working hours) 
Lifestyle intervention – diet 
Nutritionist guidance group meetings Assumptions Assume cost per hour to NOK300,-, multiplied by 1.4 to include social 
costs. 14 meeting per year, time spent for each meeting 3 hours 
(transportation and participation).  
Nutritionist guidance individual session Assumptions Assume cost per hour to NOK300,-, multiplied by 1.4 to include social 
costs. 2 sessions per year, time spent for each meeting 3 hours 
(transportation and participation). 
Lifestyle intervention – exercise 
Exercise sessions Assumptions Assume cost per hour to NOK300,-, multiplied by 1.4 to include social 
costs. 80 exercise sessions per year, time spent for each session 3 hours 
(transportation and participation). 
*Norwegian Prescription Database 
**Norwegian Labour and Welfare Administration 
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In the UKPDS Outcomes Model, the risk of complications is handled 
probabilistically while the unit costs are fixed (without distributions or uncertainty). The 
uncertainty in the risk of complications including death is expressed in the 14 risk 
equations (see appendix 5-7). To capture uncertainty in the intervention costs, we 
combined output from Monte Carlo simulation in the UKPDS model with estimations in a 
separate spreadsheet. UKPDS first provided 500 simulations of complication costs, life 
expectancies and QALYs for each of the two patient groups (two-year lifestyle intervention 
versus insulin treatment). The intervention costs were made dependent on the life 
expectancies returned by the UKPDS Outcomes Model. Furthermore, the intervention costs 
were made probabilistic in a separate EXCEL spreadsheet. We utilized the inverse gamma 
function in EXCEL, a random numbers generator (between zero and one) and an assumed 
standard deviation of plus/minus 10 percent of the intervention cost (adjusted for life 
expectancy). EXCEL then drew from a gamma distribution for each of the intervention cost 
estimates. For each of the iterations from the UKPDS Outcomes Model the intervention 
cost estimates were added to the complication costs. The sets of QALYs and total costs 
(intervention costs and complication costs) for the two-year lifestyle group and the insulin 
group) provided us with data which enabled us to perform a probabilistic sensitivity 
analysis (Online Appendix A7, Paper III).  
 
10.4. Ethical considerations 
The survey and the questionnaire were approved by the Norwegian Social Science Data 
Services and the Regional Committee for Ethical Research. Handling of the data was done 
according to the guidelines of the Norwegian Social Science Data Services and the 
Regional Committee for Ethical Research. Anonymity of respondents was secured by 
connecting numbers to the addresses and only registering the numbers in the database. The 
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list connecting addresses to the numbers was stored separated from the file with respondent 
answers. Destruction of the list of addresses ensured anonymity.   
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11. RESULTS 
A full description of demographic features of the survey sample used in Paper I and Paper 
II are shown in table 1, Paper II. 
  
11.1. Costs of diabetes in Norway 
11.1.1. Direct costs  
In 2005, there were 8,900 hospital stays with diabetes as the main diagnosis at an estimated 
total cost of NOK178 million (see table 1, Paper I). Approximately 65% of the costs were 
attributable to insulin dependent diabetes and 27% to non insulin dependent diabetes. 
Additionally, there were 53,000 hospital stays with diabetes as a secondary diagnosis 
accounting for NOK2 billion in costs. The most frequent main diagnoses when diabetes 
was a secondary diagnosis were cardiovascular diseases (31% of costs), malignancies 
(12%) and respiratory diseases (11%). 
 Of the secondary diagnoses, type 2 diabetes (E11) accounted for 65%, while type 1 
(E10) accounted for 34%. 
We explored regional differences in the data provided by Norwegian patient register 
and found that the diabetes related in-hospital costs per inhabitant were 27% higher in the 
geographic region with the highest costs compared to region with the lowest when 
accounting for admissions with diabetes as main and secondary diagnosis. The total 
national in-hospital costs would be NOK2.6 billion if all regions had the same cost level as 
the most costly, 15% more than the numbers presented in table 1, Paper I.  
 The costs related to out-patient clinic visits in hospitals amounted to NOK67 
million (table 2, Paper I). 
 The cost of services from GPs and emergency units was NOK122 million (table 2, 
Paper I) including home visits for hypoglycaemia. The cost relating to private practicing 
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specialists amounted to NOK22 million. On the basis of the survey of diabetes, the 
estimated annual number of physician home visits for hypoglycaemia was 7,800 at a cost of 
NOK4.6 million. Type 1 diabetes accounted for 58% and type 2 diabetes for 42% of the 
visits. 
 The cost of hypoglycaemic agents for treating diabetes was NOK420 million (18% 
of total costs) (table 4, Paper I) of which NOK298 million (70%) represented insulin and 
analogues (A10A) and the rest oral glucose lowering drugs (A10B). Within the insulin 
group the cost of intermediate-acting insulin (A10AC) was NOK130 million and fast-
acting insulin (A10AB) was NOK106 million. In the group of glucose lowering drugs 
(A10B) the cost of sulphonamides, urea derivatives (A10BB) was NOK53 million and 
biguanides (A10BA) NOK40 million. In the patient survey, the use of antihypertensive 
drugs was reported by 30% of the type 1 diabetes individuals (NOK10 million) and 64% of 
the type 2 diabetes group (NOK84 million), while the proportions for cholesterol lowering 
drugs were 26% (NOK20 million) and 60% (NOK182 million), respectively.  
 Expenditure on diabetes related medical equipment was NOK340 million (Table 8, 
Paper I). The largest component here was glucose tests accounting for NOK268 million 
(80% of the total). Lancets for blood sampling accounted for approximately NOK50 
million, (13% of the total).  
 Among costs estimated on the basis of the patient survey (table 4, Paper I), 
physiotherapy accounted for NOK131 million, foot therapy NOK78 million, acupuncture 
NOK39 million and nutrition guidance NOK12 million.  
 
11.1.2. Indirect costs  
The costs related to sick leave were NOK141 million (Table 7, Paper I) of which type 2 
diabetes accounted for 85%.  
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 Total costs related to time limited disability support and disability pensions 
amounted to NOK410 million (Table 9, Paper I), of which disability pensions accounted 
for NOK394 million (96%).  
 Cost of basic and supplemental benefits was estimated at NOK45 million (Table 9, 
Paper I). 
 
11.1.3. Total costs 
Total costs were NOK2.3 billion (table 2, Paper I) when hospital stays with diabetes as 
secondary diagnoses were excluded and NOK4.35 billion when they were included. The 
largest component was medicines with NOK717 million (31% of the total). The second 
largest was disability pensions with NOK410 million (18%). Medical devices contributed 
NOK340 million (15%) and hospital admissions NOK178 million (8%).  
 
11.2. Determinants of health-related quality of life among persons with diabetes 
11.2.1. Health-related quality of life and utility scores 
In total 10% of type 1 diabetes patients had problems with MOBILITY as judged from the 
EQ-5D, 3% with SELF-CARE, 19% with USUAL ACTIVITES, 34% with 
PAIN/DISCOMFORT and 35% with ANXIETY/DEPRESSION (table 2, Paper II). For 
Type 2 diabetes the numbers were 26%, 6%, 25%, 45% and 33%, respectively. The mean 
EQ-5D index score was 0.83 (SD=0.24) in type 1 diabetes and 0.81 (SD=0.22) in the type 2 
(p=0.32). For respondents without reported complications, the mean EQ-5D index scores 
were 0.90 in type 1 diabetes and 0.85 in type 2 diabetes (table 3, Paper II). Presence of one 
complication decreased values to 0.76 and 0.80. With 2 or more diabetes-related 
complications values were 0.55 and 0.64. 
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11.2.2. Regression analyses 
In the binary logistic regressions of type 1 diabetes on EQ-5D dimension responses (table 
4, Paper II), ischemic heart disease, foot ulcer, neuropathy, body mass index and receiving 
help from others were statistically significant determinants for reporting problems in the 
MOBILITY dimension. None of the covariates had impact on the SELF-CARE dimension. 
Disability pension and limitations at work had an impact on the USUAL ACTIVITIES 
dimension. Age, ischemic heart disease and neuropathy had an impact on the 
PAIN/DISCOMFORT dimension, and age, impaired vision, ischemic heart disease, 
neuropathy and fear of hypoglycaemia had an impact on the ANXIETY/DEPRESSION 
dimension. For type 2 diabetes (table 5, Paper II) age, impaired vision, stroke, neuropathy, 
body mass index and receiving help from others were statistically significant determinants 
of MOBILITY. Receiving help from others was a statistically significant determinant for 
SELF-CARE. Sex, stroke, disability pension, receiving help from others and limitations at 
work were associated with USUAL ACTIVITIES. Ischemic heart disease, neuropathy and 
hypoglycemia had an impact on PAIN/DISCOMFORT.  Age, foot ulcers, number of 
hospital admissions during the previous 6 months and fear of hypoglycemia were 
associated with ANXIETY/DEPRESSION scores.  
The tables below show the results from the analyses we performed initially with the 
stepwise approach while Tables 4 and 5 of paper II shows the full models. 
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Table 6     Binary multivariate logistic regression of responses to the EQ-5D items in type 1 diabetics, 
odds ratios (95% CI) 
 
 EQ-5D dimensions 
 Mobility Personal care Usual activities Pain and discomfort Anxiety and depression 
Sex 
(male=0, female=1) OM OM OM 
0.45 
(0.21 – 0.97)* OM 
Age 
(in 10 years) OM OM OM 
1.30 
(1.01 – 1.68)* 
0.71 
(0.54 – 0.93)* 
Impaired vision 
(no=0, yes=1)  OM 
11.02 
(1.07 – 113.80)* OM ----- 
3.98 
(1.58 – 10.01)** 
Ischemic heart disease 
(no=0, yes=1) 
22.35 
(5.24 – 95.38)*** OM OM 
6.74 
(1.57 – 28.92)* 
6.49 
(1.43 – 29.42)* 
Impaired kidney 
function (no=0, yes=1) ----- ----- ----- ----- OM 
Foot Ulcer (no=0, 
yes=1) 
13.55 
(1.77 – 103.45)* OM ----- OM OM 
Stroke (no=0, yes=1) OM OM OM OM OM 
Neuropathy (no=0, 
yes=1) 
10.67 
(2.22 – 51.38)** OM ----- 
33.24 
(3.88 – 284.79)** 
4.24 
(1.03 – 17.44)* 
Body mass index 
(kg/m2) OM ----- ----- ----- ----- 
Disability pension 
(no=0, yes=1) ----- ----- 
5.21 
(2.07 – 13.15)*** ----- ----- 
Number of hospital 
admissions during 
previous 6 months 
----- ----- ----- ----- OM 
Receives help from 
others (no=0, yes=1) ----- 
19.05 
(1.86 – 194.73)* 
5.06 
(1.71 – 14.98)** ----- ----- 
Hypoglycaemia 
index# ----- ----- ----- OM OM 
Fear of 
hypoglycaemia## 
(small=0, large=1) 
----- ----- ----- ----- 4.12 (1.93 – 8.80)*** 
Limitations at work##  
(small=0, large=1) ----- ----- 
9.22 
(3.21 – 26.51)*** ----- ----- 
Limitations socially##  
(small=0, large=1) ----- ----- OM ----- ----- 
Log likelihood -35.89 -13.85 -59.57 -88.31 -86.22 
* p<0.05, **p<0.01, ***p<0.001. Cells with dotted line indicate that the variable was not included in the 
model. OM: omitted during regression modelling 
#    Self reported episodes of hypoglycaemia, with 4 levels of severity (level 1 = hypoglycaemia cured with 
the intake of for example fluids containing sugar, no help from other required, level 2 = hypoglycaemia cured 
with the intake of for example fluids containing sugar, help from others required, level 3 = hypoglycaemia 
with help from doctor required (no hospital admission), level 4 = hypoglycaemia resulting in hospital 
admission), then added with severity weights (level 1 x 1, level 2 x 2, level 3 x 3, level 4 x 4) and finally 
divided in 3 groups 0, 1-11 and 12 to max   
##   Self reported on a scale from 1 to 5 (1 = not at all, 5 = very much), recoded to 2 levels (> and < than 2.5 
due to imputed values having values with decimals) 
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Table 7     Binary multivariate logistic regression of responses to the EQ-5D items in type 2 diabetics, 
odds ratios (95% CI) 
 
 EQ-5D dimensions 
 Mobility Personal care Usual activities Pain and discomfort Anxiety and depression 
Sex 
(male=0, female=1) OM OM 
0.52 
(0.29 – 0.96)* OM OM 
Age 
(in 10 years) 
1.44 
(1.11 – 1.88)** OM 
1.39 
(1.05 – 1.85)* OM OM 
Impaired vision 
(normal=0, 
reduced=1)  
3.22 
(1.65 – 6.25)** OM OM ----- OM 
Ischemic heart 
disease (no=0, 
yes=1) 
2.06 
(1.04 – 4.11)* OM OM 
2.86 
(1.50 – 5.46)** OM 
Impaired kidney 
function (no=0, 
yes=1) 
----- ----- ----- ----- OM 
Foot Ulcer (no=0, 
yes=1) OM OM ----- OM 
8.34  
(2.06 – 33.71)** 
Stroke (no=0, yes=1) OM OM 5.49 (1.80 – 16.78)**  OM 
Neuropathy (no=0, 
yes=1) 
11.44 
(3.38 – 38.67)*** OM ----- Predicts perfectly# OM 
Body mass index 
(kg/m2) 
1.11 
(1.05 – 1.18)*** ----- ----- ----- ----- 
Disability pension 
(no=0, yes=1) ----- ----- 
2.72 
(1.40 – 5.26)**  ----- 
Number of hospital 
admissions during 
previous 6 months 
----- ----- ----- ----- 1.70  (1.07 – 2.71)* 
Receives help from 
others (no=0, yes=1) ----- 
8.84 
(3.49 – 22.39)*** 
5.67 
(2.84 – 11.33)*** ----- ----- 
Hypoglycaemia 
index## ----- ----- ----- 
1.68 
(1.14 – 2.48)** OM 
Fear of 
hypoglycaemia### 
(small=0, large=1) 
----- ----- ----- ----- 5.71  (3.46 – 9.41)*** 
Limitations at 
work### (small=0, 
large=1) 
----- ---- 7.61 (4.06 -14.26)*** ----- ----- 
Limitations 
socially### 
(small=0, large=1) 
----- ---- OM ----- ----- 
Log likelihood -172.80 -69.17 -139.17 -234.44 -191.62 
* p<0.05, **p<0.01, ***p<0.001, # All patients reporting neuropathy also reports having problems in the 
“pain and discomfort” dimension of the EQ-5D.  Cells with dotted line indicate that the variable was not 
included in the model. OM: omitted during regression modelling 
##    Self reported episodes of hypoglycaemia, with 4 levels of severity (level 1 = hypoglycaemia cured with 
the intake of for example fluids containing sugar, no help from other required, level 2 = hypoglycaemia cured 
with the intake of for example fluids containing sugar, help from others required, level 3 = hypoglycaemia 
with help from doctor required (no hospital admission), level 4 = hypoglycaemia resulting in hospital 
admission), then added with severity weights (level 1 x 1, level 2 x 2, level 3 x 3, level 4 x 4) and finally 
divided in 3 groups 0, 1-11 and 12 to max   
###   Self reported on a scale from 1 to 5 (1 = not at all, 5 = very much), recoded to 2 levels (> and < than 2.5 
due to imputed values having values with decimals) 
 
In the linear regression of the EQ-5D index for type 1 diabetes, presence of 
ischemic heart disease had a negative impact (-0.181), along with stroke (-0.291), 
neuropathy (-0.358), receiving disability pension (-0.111) and social limitations (-0.107) 
(table 6, Paper II). 
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For type 2 diabetes the following conditions had a negative impact on the EQ-5D 
index (table 6, Paper II): stroke (-0.135), neuropathy (-0.187), disability pension (-0.100), 
receives help from others (-0.123), fear of hypoglycaemia (-0.078) and limitations at work 
(-0.087).  
 
11.3. Cost-effectiveness analysis of a lifestyle intervention versus insulin 
With immediate switch to insulin treatment, the estimated discounted life expectancy was 
9.44 years (7.67 QALE), while it was 9.48 (7.71 QALE), 9.53 (7.75 QALE) and 9.64 (7.86 
QALE) for two-year, five-year and lifelong lifestyle intervention (table 1, Paper III). The 
discounted lifetime total costs including indirect costs of the four programmes were, 
NOK283,637, NOK512,540, NOK799,245 and NOK1,417,004, respectively. Compared 
with scenario 1, the costs per incremental life year were NOK6,053,073, NOK6,209,362 
and NOK5,832,427 for two-year, five-year and lifelong lifestyle intervention, respectively. 
Finally the costs per incremental QALY were NOK6,040,995, NOK6,350,144 and 
NOK5,863,067 for the respective courses of treatment. 
 The costs of the lifestyle program were estimated at NOK135,296 in the first year 
and NOK133,796 in the subsequent years. Costs were higher in the initial year due to the 
overhead costs of the program. Direct costs consisted of overhead costs NOK1,500, costs 
of running the diet part of the program (NOK5,902) and costs of the exercise program 
(NOK6,933). Indirect costs consisted of time to participate and travelling to the session and 
were estimated to be NOK20,160 for the diet sessions and NOK100,800 for exercise 
sessions.  
 The largest contributor to costs were indirect costs incurred by the patients’ 
participation in diet and exercise sessions and time spent on travelling to these session. 
When indirect costs were set equal to zero, the estimated discounted total costs of the four 
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programmes were NOK283,637, NOK585,178, NOK288,125 and NOK290,142, 
respectively. The incremental analyses (each course compared with immediate switch to 
insulin) resulted in a costs per incremental life year of NOK40,738, NOK54,052 and 
NOK33,473 for two-year, five-year and lifelong lifestyle intervention, respectively 
(NOK40,656, NOK55,277 and NOK33,649 per QALY). 
 When the impact of the lifestyle program on HbA1c was increased with 5% for 
two-year, five-year and lifelong lifestyle interventions, the life expectancy and QALE’s 
were 9.53 (7.75), 9.60 (7.82) and 9.69 (7.92) respectively. Immediate change to insulin was 
kept unchanged. This change led to an increase in life expectancy of 0.046 (16.9 days, 
0.49%), 0.071 (26 days, 0.75%) and 0.054 (19.9 days, 0.56%) and QALY’s of 0.046 (16.9 
days, 0.60%), 0.069 (25 days, 0.89%) and 0.055 (20 days, 0.70%) for two-year, five-year 
and lifelong lifestyle program, in that order. With this increase in impact on HbA1c, the 
cost per QALY of NOK2,692,540, NOK3,451,426 and NOK4,580,114 for the two-year, 
five-year and lifelong programmes. Without indirect costs, all lifestyle programmes 
became dominant strategies (lower cost and better effect) when compared to immediate 
insulin.  
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12.    DISCUSSION 
12.1. Cost-of-diabetes in Norway 
The results of the cost-of illness study clearly indicate that diabetes places a considerable 
financial burden on patients and the Norwegian society. The total costs of treating diabetes 
in Norway in 2005 amounted to about NOK2.3 billion or 1.3% of total health care 
expenditures, or 2.5% if all diabetes related hospital stays are included. Interestingly, 
patient expenditures for acupuncture, physiotherapy and foot therapy were many times 
those of nutritional guidance. In addition, diabetes imposes costs to society in terms of lost 
production from job absenteeism and premature mortality.  
Two important issues to keep in mind when accounting for costs of diabetes are the 
assumed large number of individuals with type 2 diabetes that remain undiagnosed. The 
costs of these patients are not included in our estimates. Furthermore some studies point to 
the probability of diabetes being under-reported. One example is a resent Scottish study 
(73) which aimed to assess the completeness of coding of diabetes in hospital inpatient 
admissions. The study population was patients identified with diabetes prior to hospital 
admission. Data were derived from linking the Scottish National Diabetes Register and 
hospital admissions. The authors found that only 59% of hospital inpatient admissions for 
people previously diagnosed with diabetes mentioned diabetes as a diagnosis at discharge 
from hospital. Meanwhile, over 99% of people with hospital records stating diabetes were 
included in the diabetes register. Regarding diabetes as a co-morbidity, completeness 
varied by primary diagnosis, Admissions with coronary heart disease and cancer as the 
primary diagnosis mentioned co-existing diabetes in 70% and 41% of the cases, 
respectively. A conclusion in the study is that hospital data alone considerably 
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underestimates the number of admissions and bed days but overestimate length of stay for 
people with diabetes.  
Our study results need to be viewed in the context of potential limitations: some 
costs may be underestimated, some costs may be overestimated and some costs are omitted. 
Most of the limitations were mentioned in Paper I, but some limitations were omitted or 
only briefly discussed due to space limitations. Of particular interest are indirect costs or 
production losses due to diabetes. We did not account for productions losses from diabetes-
related premature mortality because we adopted the prevalence approach. Diabetes may 
reduce life expectancy (7), and premature mortality represents a considerable productivity 
loss. 
 In principle, a cost-of-illness analysis should provide an estimate of the diabetes-
attributable costs. The World Health Organization has the following definition of 
attributable fraction (74): “The contribution of a risk factor to a disease or a death is 
quantified using the population attributable fraction (PAF). PAF is the proportional 
reduction in population disease or mortality that would occur if exposure to a risk factor 
were reduced to an alternative ideal exposure scenario (eg. no tobacco use)”. Because 
diseases may have many causes that interact, it is not easy to estimate the attributable 
fraction. The same type of arguments applies for the diabetes attributable costs (costs that 
would be avoided if all diabetes were eliminated). Even with precise estimates of all health 
care utilization with diabetes as a primary or secondary diagnosis, we cannot estimate the 
diabetes attributable costs because the diabetes related complications may have multiple 
causes. 
Diabetes may cause complications such as cardiovascular disease, renal failure, 
retinopathy, erectile dysfunction and others that incur costs. It is not easy to capture all 
these costs unless diabetes is stated as a main or secondary diagnosis when such 
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complications are treated. To the extent diabetes is stated as a secondary diagnosis at 
discharge from hospital, such costs are included in the NOK4.3 billion estimate. With 
respect to some of the complications, however, there are many causal factors and no 
reliable data on the fraction attributable to diabetes. 
 When estimating the cost of in-hospital care on the basis of the main diagnosis, 
hospital stays will not be included in the cost analysis if the diabetes diagnosis is not stated. 
Because hospitals in Norway have partial DRG financing, the choice of primary diagnosis 
may be influenced by the financial consequences of choice. Such incentives, however, 
would imply that doctors are likely to look for secondary diagnoses in order to increase 
reimbursements. Clearly, if a patient has impaired glucose tolerance (IGT), but a diabetes 
diagnosis has not been made, the costs of IGT will not be included in our results. The 
results of a Norwegian study indicate that diabetes patients tend to have higher costs than 
the average patient within certain DRGs (75). To the extent that this is the case, our 
estimates are biased downward.  
In 2011 the Norwegian Directorate of Health performed an internal revision of the 
coding of diagnoses in Norwegian hospitals7.  The revision checked the agreement between 
reported codes to the Norwegian Patient Register and codes registered in electronic patient 
charts. 4000 in- and outpatient visits, from different hospitals in all health regions in 
Norway were selected at random. The revision found agreement between main diagnosis 
reported to the NPR and main diagnosis in patient charts, in 80.5 percent of the cases. 
Approximately half of deviations were unexplained and were scheduled for a follow up and 
control.    
A lack of diabetes diagnosis may also bias costs related to disability pensions and 
sick leave, physician visits, out-patient clinic visits and certain other types of services 
                                                 
 
7 www.helsedirektoratet.no/finansiering/medisinsk-koding-og-kodeverk/medisinsk-
koding/Documents/nasjonal-internrevisjon-medisinsk-kodepraksis-oktober-2011.pdf 
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where the costing is based on diagnosis. Finally, costs based on patient reported use of care 
may be underestimated because patients do not recall all use of care.  
 We have included some types of costs that are rarely included in cost-of-diabetes 
studies, such as doctor home visits related to hypoglycaemia, nutritionist guidance, foot 
therapy, physiotherapy and acupuncture. We cannot attribute all costs gathered in the 
patient survey to diabetes. For example, there are reasons other than diabetes for having 
acupuncture. It should be noted also that the survey we undertook may not be entirely 
representative of the diabetes population in Norway, especially for type 2 diabetes. In 
conclusion, the cost data are likely to be complete for drugs and devices, while other 
estimates may be biased.  
While several cost data are uncertain, some are likely to be complete and correct. 
The NLWA keeps account of reimbursement for diabetes related medical devices and these 
costs are likely to be complete. Also, drug costs are quite accurate because all pharmacies 
register prescriptions electronically and transfer their data to the central registry.  
 In economics, the term cost is related to the concept of opportunity cost (the value 
of the resources used in the best alternative project). Prices in a well functioning market are 
supposed to represent opportunity cost. In the area of health care, markets are not well 
functioning because of patients’ lack of information and government interventions (public 
subsidies and monopoly because of patent protection). This means that few if any unit costs 
represent opportunity costs, but this fact applies to all cost-of illness studies.   
 Despite possible methodological weakness, this study provides some general 
lessons. First, the main direct cost-drivers from diabetes are hospital services, 
pharmaceuticals and medical devices. These services are reimbursed in part or in full by 
governments in most industrialised countries. Second, other types of services such as foot 
therapy, physiotherapy, and acupuncture may represent considerable costs, but often 
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receive only partial and sometimes no reimbursement by governments. In Norway, the use 
of foot therapy is paid entirely by the patient, while the cost of foot ulcer treatment and 
amputations is covered almost fully by the government. This may seem paradoxical as 
untreated foot ulcers may lead to infections and ultimately amputation. Finally, the study 
reveals a high level of spending on acupuncture compared to much lower spending on 
nutritional guidance. Given the importance of diet for the progress of the disease, this result 
is somewhat paradoxical and suggests that patients could benefit from a different spending 
pattern. 
 The hospital costs with diabetes as main diagnosis were twice as high for type 1 
diabetes as for type 2. However, the high frequency of cardiovascular disease with type 2 
diabetes as the secondary diagnosis group indicates that type 2 diabetes is a major cost 
driver. The use of antihypertensive and cholesterol lowering drugs in our survey supports 
this view. 
 The number of patients on oral glucose lowering drugs was almost twice the 
number of users of insulin and analogues. In terms of costs, the pattern was opposite in that 
the total cost of insulin and analogues was twice the cost of oral glucose lowering drugs. 
This indicates that treatment of type 2 diabetes becomes more costly with disease 
progression because insulin is increasingly prescribed with progression.  
 Our results are somewhat different from those reported elsewhere. In Sweden the 
estimated costs of hypoglycaemia related to type 2 diabetes was €14.10 per patient per year 
(76) while our data would suggest approximately €3 per patient. The Swedish costs are 
higher because of a higher reported prevalence of hypoglycaemia and the inclusion of 
indirect costs.     
 When comparing our results with those of other studies one should be aware of 
methodological differences. We used a prevalence approach while studies relying on an 
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incidence approach with prediction of future costs may yield higher values. Also, the 
method for valuing absence from productive work may have considerable impact on the 
results of cost-of-diabetes studies. Clearly, the more types of diabetes related costs that are 
included, the higher the estimated costs. A recent review (41) suggests that there is a 
general tendency, heavily influenced by cost components included in the estimates, for 
indirect costs to make up a slightly larger proportion of total costs than direct costs. In the 
studies reviewed, the proportion of indirect costs was in the range of 25-64%. The review 
suggests a number of potential improvements in cost-of diabetes studies: the use of disease 
specific attributable risk procedures, new approaches to elicit the impact of co-morbidities, 
better methods for capturing cost information from new sources such as databases of 
managed care organizations, use of national patient surveys, the development of standards 
for estimating the costs and explicitly reporting the purpose of the diabetes cost study. 
 As an example of the differences seen in cost-of-illness studies, a German study 
(20) found that in 2001 the direct costs of diabetes accounted for 14% of total health care 
expenditure. This study compared costs of diabetes with a matched control group, finding 
that excess cost of diabetes accounted for 6.8% of total health care expenditure. Medicines 
accounted for 22% of excess costs. Indirect costs were 48% of the costs included.   
 A study performed in Ireland (77) estimated that the costs of treating type 2 
diabetes represented 4.1% of the total health care expenditure. Hospitalisations accounted 
for almost half of overall costs, while ambulatory and medicines costs accounted for 27% 
and 25%.  
 In a Swedish (19) study, the costs of diabetes amounted to 5.7 billion Swedish 
Kroner (SEK). Direct costs were estimated to be 43% of total costs. Hospital care estimates 
were based on main diagnosis and were the main component of direct costs. Indirect costs 
in the Swedish study were significantly higher than our findings in Norway. This may be a 
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result of differences in diagnosis setting. The Swedish study includes costs related to 
productivity losses caused by premature mortality. The average age of retirement in 
Norway is around 60 (78). It seems unlikely that a significant number of diabetics die 
before this age.  
 In conclusion, the cost consequences of diabetes seem to be smaller in Norway than 
what has been observed in some other countries. The question is whether such differences 
are due to underestimations in this study, overestimation in other studies or real cost 
differences. It may be worthwhile noting that Norway generally has good register data, and 
it is not obvious that data limitations are less in other countries.  
 
12.2. Health-related quality of life in diabetes 
In this study, diabetics with complications had considerably reduced HRQoL, even though 
the impact on HRQoL was somewhat different for type 1 and type 2 diabetes. Stroke and 
neuropathy seem to have negative impact on overall HRQoL in both types of diabetes, 
while ischemic heart disease and social limitations impact on type 1 diabetes and fear of 
hypoglycaemia and limitations at work seem to impact negatively on type 2 diabetics. 
Being on disability pension is associated with reduced HRQoL in both types of diabetes, 
while receiving help from other people is significant only in type 2 diabetes. 
Persons with type 1 diabetes reported more problems in the PAIN/DISCOMFORT 
and ANXIETY/DEPRESSION dimensions than persons with type 2 diabetes, while in the 
MOBILITY, SELF-CARE and USUAL ACTIVITIES dimensions the pattern seemed to be 
opposite.      
 Some limitations of the study should be noted. The respondents in the survey may 
not be representative of the diabetes population. A large proportion of the persons with type 
1 diabetes in Norway (approx. 20,000) are members of the NDA while only a smaller 
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proportion of the type 2 (approx. 100,000) diabetics are registered. Clearly, our study does 
not capture HRQoL in undiagnosed diabetes patients. In line with other patient surveys, we 
had 40% non-response.  
Lacking a Norwegian EQ-5D tariff we used the UK tariff (25;79). This tariff is 
probably the most commonly used EQ-5D tariff globally, and quite similar to the Danish 
(80) and US (54;55) ones. Also, one small Norwegian study indicates that UK and 
Norwegian values are quite similar (81).  
 In spite of the limited descriptive system of the EQ-5D, the instrument captures the 
impact of several diabetes complications both with respect to each of the dimensions and 
the EQ-5D index (Table 4, 5 and 6, Paper II). Ischemic heart disease, stroke and 
neuropathy, in particular, have a significant impact. Surprisingly, impaired vision had no 
impact on the MOBILITY dimension for persons with type 1 diabetes.    
 In our study, persons with type 1 diabetes had higher HRQoL than those with type 
2. This is plausible because the former were younger. Interestingly, the difference was 
opposite in those with complications, and it seems as if diabetic complications have more 
impact on HRQoL in type 1 diabetes than type 2.  
 Some other studies have used the EQ-5D in populations with diabetes. In the 
UKPDS 37 study (82) persons with type 2 diabetes and no complications had a mean EQ-
5D index value of 0.83 while we found 0.85. For type 2 patients with complications, our 
observed EQ-5D index value (0.73) was equal to that of the UKPDS 37 study. Taking into 
account that patient characteristics were similar in the UKPDS and our study, UK diabetes 
studies may be transferable to the Norwegian setting.  
 In another UK study (83) (only type 2 diabetes) the change in utility associated with 
fear of hypoglycaemia was relatively small compared to the disutility for serious diabetic 
complications such as neuropathy. Similarly, in our study fear of hypoglycaemia caused a 
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fairly small reduction in utility of 0.021 (type 1 diabetes) and 0.078 (type 2), but the 
disutility of neuropathy was larger with 0.358 (type 1 diabetes) and 0.187 (type 2 diabetes). 
 In a US review (84) of body weight and HRQoL in type 2 diabetes, the authors 
found decreasing HRQoL with increasing body weight in all included studies. When 
adjusting for other explanatory variables, we observed no significant impact of BMI on 
HRQoL.  
 A subgroup of unspecified type diabetics (n=117) in a Swedish general population 
EQ-5D study (85) (UK tariff) reported a higher frequency of problems in all dimensions of 
the EQ-5D, than in both diabetes categories in our study. Further, the Swedish diabetics 
had a lower mean EQ-5D index (0.74) than we observed in both type 1 and type 2 diabetes. 
 Diabetes complications may have an impact on many dimensions of quality of life, 
and the impact may be substantial. The strongest determinants of reduced HRQoL among 
persons with diabetes were ischemic heart disease, stroke and neuropathy. 
 
12.3. Cost-effectiveness of lifestyle intervention in diabetes 
Paper III indicates that lifestyle interventions are not cost-effective unless society 
disregards indirect costs. Compared with immediate switch to insulin treatment, the costs 
per incremental QALY were NOK6.041 mill, NOK6.350 mill and NOK5.863 mill for the 
two-year, five-year and lifelong lifestyle intervention (Table I, Paper III). When the cost of 
time related to travel and participation in the diet and exercise sessions were disregarded, 
the costs per incremental QALY for the respective treatment courses were NOK40,656, 
NOK55,277 and NOK33,649 (Table I, Paper III).  
The strengths of the study lies in the use of real life clinical trial data and a well 
documented economic model (23). A limitation in our study is that the UKPDS Outcomes 
Model does not account for changes in BMI because weight was not a significant predictor 
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in the underlying regression analyses. In fact, body weight had an impact on the probability 
of having heart failure, only, and the effect was relatively small (23). We accounted for 
changes in body weight by applying a reduced weight throughout the remaining life years 
in all lifestyle intervention programmes, and this assumption will favour the lifestyle 
interventions.   
 Unfortunately, the ILIP trial did not report values for HbA1c, total and HDL 
cholesterol, HDL or systolic blood pressure at the time of diagnosis of type 2 diabetes. 
Lacking these data we used data from entry into the ILIP trial as a proxy for values at 
diagnosis. This assumption may be realistic because these patients are likely to be poorly 
controlled both at the time of diagnosis and when the next step is administering insulin 
(similar to patients at inclusion in the study). Patients who sign up for participation in 
lifestyle interventions programs are likely to be highly motivated and may not be 
representative of the average diabetes population. This, however, may not be a significant 
weakness of this economic study because lifestyle intervention should only be offered to 
highly motivated individuals. Some costs, however, may be incurred by the search for such 
motivated patients.  
 The UKPDS Outcomes Model is based on data from an intervention study 
performed up to 30 years ago. The relationship between diabetes complications and their 
predictors may therefore have changed considerably over time and place (UK versus 
Norway). Some or all of the risk equations may therefore be somewhat outdated. For 
instance the model may not take into account the full benefits of the effect statins have had 
on population cholesterol levels and thus risk of developing heart disease. This will 
however benefit all groups and may not cause major bias in the modelling results. The use 
of UK rather than Norwegian risk data may also represent a limitation. 
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Few economic studies of lifestyle intervention for diabetes have been published. In 
a Dutch study, the long term cost-effectiveness of lifestyle interventions for manifest type 2 
diabetes was modeled [21] based on different clinical trials. The average gain in QALYs 
gain ranged from 0.01 to 0.14. In our study, QALY ranged from 0.04 for the two-year 
lifestyle intervention program to 0.19 for the lifelong lifestyle intervention program. The 
Dutch study only took direct costs into account and concludes that lifestyle interventions 
are likely to “yield important health benefits at reasonable costs”, which is in line with our 
study when we disregard indirect costs. The authors state that essential evidence for long-
term maintenance of health benefits was limited and that future research should be focused 
on long-term effectiveness of such programs.  
 The Diabetes Prevention Program (DPP) in the US (86), including metformin and 
intensive lifestyle interventions seems to reduce the incidence of type 2 diabetes compared 
with a placebo intervention. A study based on the DPP (87), indicate that the lifestyle and 
metformin interventions were cost-effective relative to placebo intervention. Both direct 
and indirect costs were taken into account in this study. 
 
12.4. General discussion 
The findings of these studies (Paper I-III) indicate that diabetes is a costly disease for both 
society and the individual with diabetes. The expected increase in prevalence of type 2 
diabetes caused by aging population and increasing body weight in most industrialised 
countries should alarm decision makers of increasing costs in the future. Diabetes is a 
global and national challenge for populations, health care systems and budgets.  
 Viewing diabetes from a global perspective, the World Health Organization 
published in 2010 the Global status report on non-communicable diseases (NCD) (88). 
Almost 36 million of the 57 million global deaths in 2008 were a result of NCDs. Diabetes 
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accounted for 1.3 million deaths and is listed among the main NCDs along with 
cardiovascular diseases, cancers and chronic lung diseases. The three latter accounted for 
17, 7.6, 4.2 million deaths, respectively. Tobacco, alcohol use, unhealthy diet, too little 
physical activity are claimed to be leading causes of NCDs. The report claims that 
interventions on population level may reduce the impact of NCDs, and highlights measures 
such as increasing tobacco and alcohol, tobacco control and reducing salt consumption. 
The report claims that heart disease, stroke and diabetes cause large reductions in national 
income each year, and furthermore that economic analyses have indicated that a 10% rise 
in NCDs may annually impact economic growth rate with a reduction of 0.5%. The report 
has a strong emphasis on prevention and early detection. This is to avoid progression to 
more severe and costly disease, and the lurking complications. For diabetes the following 
interventions are suggested: blood pressure control, glycaemic control and foot care. The 
reports project a large increase in global burden of NCDs in the coming decades. 
Our studies are performed in the context of Norway and our local challenges. The 
results of the studies we have performed provide information on the complex cost structure 
of diabetes. Furthermore we have found that the complications ischemic heart disease, 
stroke and neuropathy are what decreases HRQoL most in groups of individuals with 
diabetes. Finally we observe that an intensive lifestyle program may be an alternative to 
insulin treatment in highly motivated groups, but whether such interventions are cost-
effective is largely depending on how indirect costs are considered. Another challenge is 
how to recruit motivated patients.   
The findings in our survey indicate that there is little emphasis on nutritional 
guidance and advice among individuals with diabetes. It seems paradoxical that large 
resources are used for treating complications associated with diabetes while prevention has 
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less emphasis and is not reimbursed. Another example of this paradox lies in the fact that 
foot-therapy is not publicly funded while amputations are. 
The Norwegian association of GP’s (NSAM) expresses concerns in their guidelines 
(89) regarding the increasing prevalence of obesity in Norway, not least among immigrant 
groups in which up to 55% of women are obese. The guidelines recommend lifestyle 
changes with change in diet and physical activity. Even though such recommendations may 
be reasonable, they may not be cost-effective. Our study indicates that individual 
interventions are cost-effective only if we disregard the cost of time and lost productivity. 
This is in line with a previous study of prevention of cardiovascular disease (90). Here, the 
authors conclude that individual based prevention is not cost-effective while interventions 
targeting groups of individuals are. Society may do well in considering more large scale, 
population based interventions aimed at prevention of diabetes. One example of such a 
population is immigrant women. In other areas of medicine we have seen how information 
and added knowledge have managed to change the attitude towards certain kinds of foods. 
One example is the changed view on fat and the moving-away from trans-fat and saturated 
fat during the last 30-40 years. In Norway, cardiovascular mortality is now less than 50% 
of what it was 30 years ago8. Even though some of this improvement is attributable to 
better medical treatment, changes in lifestyle also play a role. 
 
12.5. Need for further research 
Countless scientific papers conclude that more research is needed even though “important 
findings have been reported in this study”. This thesis is no exception. The high costs of 
diabetes care may in itself indicate that more research is needed. The main argument in 
favour of more research does not lie in lowering of the diabetes costs. In fact, advances in 
                                                 
 
8 Public Health Report, the Health State in Norway, Norwegian Institute of Public Health, Oslo, 2010. 
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health care are usually entailed by increased costs. The main argument lies in a better life 
for the patients: Less symptoms and complications and longer life – in other words more 
QALYs.  
The findings in our research point to two main areas of research in Norway and 
elsewhere. First, society needs more information on interventions that can prevent the 
development of diabetes and its complications. Even though lifestyle interventions are seen 
as the cornerstone of diabetes treatment, the evidence that such interventions are effective 
is more limited. Not least, there is a need for long term follow up of patients in such trials. 
Second, there is a need to develop better and more up to date economic models of diabetes. 
Even though the UKPDS Model is based on a large trial, its parameter values may be 
outdates due to more use antihypertensive and lipid lowering drugs. Here, the Nordic 
countries could and should play a role because of the access to high quality register data. 
The HUNT study is an example of what potentials Nordic epidemiology has (91-109). By 
means of clinical trials and economic evaluation, policy makers may be able to develop 
sustainable policies to handle the increasing challenge of diabetes. 
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Diabetes: cost of illness in Norway
Oddvar Solli1*, Trond Jenssen2,3, Ivar S Kristiansen1,4
Abstract
Background: Diabetes mellitus places a considerable burden on patients in terms of morbidity and mortality and
on society in terms of costs. Costs related to diabetes are expected to increase due to increasing prevalence of
type 2 diabetes. The aim of this study was to estimate the health care costs attributable to type 1 and type 2
diabetes in Norway in 2005.
Methods: Data on inpatient hospital services, outpatient clinic visits, physician services, drugs, medical equipment,
nutrition guidance, physiotherapy, acupuncture, foot therapy and indirect costs were collected from national
registers and responses to a survey of 584 patients with diabetes. The study was performed with a prevalence
approach. Uncertainty was explored by means of bootstrapping.
Results: When hospital stays with diabetes as a secondary diagnosis were excluded, the total costs were €293
million, which represents about 1.4% of the total health care expenditure. Pharmaceuticals accounted for €95
million (32%), disability pensions €48 million (16%), medical devices €40 million (14%) and hospital admissions €21
million (7%). Patient expenditures for acupuncture, physiotherapy and foot therapy were many times higher than
expenditure for nutritional guidance. Indirect costs (lost production from job absenteeism) accounted for €70.1
million (24% of the €293 million) and included sick leave (€16.7 million), disability support and disability pensions
(€48.2 million) and other indirect costs (€5.3 million). If all diabetes related hospital stays are included (primary- and
secondary diagnosis) total costs amounts to €535 million, about 2.6% of the total health care expenditure in
Norway.
Conclusions: Diabetes represents a considerable burden to society in terms of health care costs and productivity
losses.
Background
Diabetes mellitus places a considerable burden on
patients in terms of morbidity [1] and mortality [2] and
on society in terms of costs [3-5]. The prevalence of
type 2 diabetes is increasing in many countries [6]
including Norway [7]. The number of patients with type
1 diabetes has been estimated at 25,000 [8]. In 2005,
117,600 persons in Norway were treated with insulin or
oral antidiabetics [9]. We then assume that 92,600 of
them have type 2 diabetes. In the Norwegian HUNT
study [10] the proportion of patients with type 2 dia-
betes that was not on antidiabetic pharmaceuticals was
30%. This would imply that the total number of patients
with type 2 diabetes is 132,300 (92,600/0.7) [8-11].
Additionally, a large number of persons with type 2
diabetes are assumed to be undiagnosed. It has been
estimated that about 3-4% of the population above the
age of 30 have type 2 diabetes [8].
Cost-of-illness analysis is a type of study that has been
designed to quantify and value all economic conse-
quences of a disease without taking into account the
benefits of treatment. Therefore, cost-of-illness analysis
in itself may not guide priority setting, but may be use-
ful in designing financing systems and setting priorities
for research.
There are two main approaches to cost-of-illness ana-
lysis: the prevalence [3,12-15] and the incidence [16]
approach. The former accounts for all prevention, treat-
ment and rehabilitation costs incurred during a given
year, while the latter measures all such costs for new
cases of the disease in a given year (the index year).
Future treatment costs are accounted for by estimating
the future costs for all individuals who develop the dis-
ease in the index year, and the present value of the
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costs are added to the costs incurred in the index year.
The prevalence approach has the advantage of relating
to measures of total annual health care expenditure, and
it may yield more accurate estimates because it is based,
at least in principle, on observed costs rather than pro-
jected ones. The advantage of the incidence approach
lies in the fact that it provides projections of future
costs that may be very different from current ones when
incidence is increasing or declining. Such projections,
however, may be uncertain.
The aim of this study was to quantify, using the preva-
lence approach, the societal costs in Norway of type 1
and type 2 diabetes, including indirect costs (productiv-
ity losses from diabetes).
Methods
The study was based on register data for the entire Nor-
wegian population (n = 4.6 million). In addition we per-
formed a survey of 584 persons with diabetes. We
aimed at including all diabetes related costs, but some
data were unavailable (e.g. depression, erectile dysfunc-
tion, neuropathic pain, osteoarthritis, congestive heart
failure and pulmonary disease).
Direct costs
Direct costs are the costs of detection, treatment, pre-
vention, rehabilitation and long-term care arising from
an illness. In theory, all relevant health care and non-
health care costs are included, but in practice there is a
limit to what can be identified and measured. Data
were, as far as possible, captured for 2005 and expressed
in 2005 EURO (1 € ≈ 8.50 Norwegian Kroner).
Inpatient hospital services
From the Norwegian Patient Register (NPR) we
obtained information on all hospital stays with the fol-
lowing ICD-10 codes as main or secondary diagnosis:
E10 (insulin-dependent diabetes mellitus), E11 (non-
insulin-dependent diabetes mellitus), E23.2 (diabetes
insipidus), H28.0 (diabetic cataract), N08.3 (glomerular
disorders in diabetes mellitus), O24 (diabetes mellitus in
pregnancy), P70.0 (syndrome of infant of mother with
gestational diabetes), P70.1 (syndrome of infant of a dia-
betic mother), P70.2 (neonatal diabetes mellitus), R73.0
(abnormal glucose tolerance test) and Z13.1 (special
screening examination for diabetes mellitus). For each
stay we obtained anonymous data on the primary diag-
nosis, secondary diagnosis, age, gender, geographic loca-
tion, length of stay and DRG-weight. In Norway,
patients receive a main diagnosis and possibly one or
more secondary diagnoses at discharge from hospital.
ICD10 has been used since 1999. On the basis of the
diagnoses, age, sex and possibly procedures, patients are
allocated to a diagnosis related group (DRG). The
Directorate of Health performs annual cost studies of a
representative sample of hospitals in order to estimate
the mean hospital costs of patients in each DRG. Even
though the cost estimate may be incorrect for the indi-
vidual patient, on average they represent reasonable
costs for the different types of patients. Hospital services
are provided by five Regional Health Authorities, each
with an independent board. Regional variation was ana-
lysed according to these units.
Outpatient clinic visits
Using the same ICD-10 codes as for inpatient services,
data on the costs of outpatient clinic visits were pro-
vided by The Norwegian Labour and Welfare Adminis-
tration (NLWA). No data for 2005 were available so
data for 2006 were used. The NLWA data encompasses
government reimbursements to hospitals. We added the
standard patient co-payment per visit (€31). According
to the financing model for hospitals, reimbursements
and co-payments encompass 40% of the estimated out-
patient clinic costs. The sum was therefore adjusted
upwards by a factor of 2.5.
Physician services
Data on the use of general practitioner (GP) services
and private specialists were obtained from NLWA.
Claim forms, 90% of which are delivered electronically
to NLWA, are provided with ICPC codes. We obtained
data on all visits with ICPC codes T89 (insulin-depen-
dent) and T90 (non-insulin-dependent) diabetes. For
each patient contact, we obtained data on diagnosis,
type of contact, reimbursement and patient co-payment.
Drugs
The Norwegian Prescription Registry (NPR) contains
information on all prescriptions redeemed from pharma-
cies. We obtained data for 2005 on the following cate-
gories of ATC codes: A10A (insulin and analogues) and
A10B (glucose lowering drugs). Additionally, we included
the costs of patient reported use of antihypertensive
drugs and cholesterol lowering drugs according to a
patient survey (see “Other types of health care”). Based
on data from the NPR we estimated average costs for one
year of treatment with antihypertensive drugs (€154) and
cholesterol lowering drugs (€357). This was based on
market share of the different drugs available, average
dose and prices.
Medical equipment
The NLWA keeps account of reimbursement for
diabetes self-tests and insulin injection equipment
(injection catheters, insulin pens and needles, syringes,
lancets for blood sampling). To avoid double counting,
the costs of insulin pumps were excluded. Insulin
pumps are administered in hospitals and costs are
captured in the DRG costing system.
Other types of health care
For various other types of resource use where register
data are not available, we obtained information through
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a self-administered questionnaire. A sample of persons
with diabetes (n = 1,000) was randomly drawn from the
membership file of the Norwegian Diabetes Association
(36 000 members in 2006. This file is assumed to
encompass most of the individuals in Norway with type
1 diabetes and about 15 000 with type 2 diabetes.
We developed a comprehensive questionnaire in colla-
boration with persons with diabetes and doctors with
diabetes care experience. The questionnaire was mailed
to the sample patients in May 2007. Non-responders
were followed up twice. Finally we had 584 responses
that could be used in further analyses. The respondents
were asked to state their use of the following types of
health care services considered to be relevant among
persons with diabetes for the previous three months:
physiotherapy, acupuncture, nutrition counselling and
GP home visits for hypoglycaemia. They were also asked
questions about the duration of the diabetes, type of
treatment and occurrence of diabetic related complica-
tions. To provide measures of the uncertainty of the
estimates we derived confidence intervals by applying
bootstrapping, 10 000 draws with replacement. The
questionnaire was approved by Regional Committees for
Medical Research Ethics and Norwegian Social Science
Data Services. Treatment costs were estimated by
assigning unit costs to the reported consumption of
health care services. Unit costs were taken from profes-
sional organizations (physiotherapy, acupuncture) and
GP’s fee schedule [17].
Indirect costs
Lacking data on productivity losses from diabetes, we
used payments of disability pension and economic sup-
port for diabetes related costs as a proxy for indirect
costs. Disability pension and economic support are
funded by the NLWA. We obtained data on all payments
in 2005 for the ICD-10 diagnoses: E10, E11, E23.2, H28.0,
H36.0, N08.3, O24, P70.0, P70.1, P70.2, R73.0 and Z13.1.
A search was performed with all equivalent ICD-9 codes
as well. Furthermore, the following ICPC codes were
included: T89 (insulin-dependent diabetes mellitus), T90
(non-insulin-dependent diabetes mellitus), W85 (diabetes
during pregnancy) and F83 (retinopathy).
Results
Inpatient hospital services
In 2005, there were 8 900 hospital stays with diabetes as
the main diagnosis at an estimated total cost of €21 mil-
lion (Table 1). About 65% of the costs were attributable
to insulin-dependent diabetes and 27% to non-insulin-
dependent diabetes. Additionally there were 53 000
hospital stays with diabetes as a secondary diagnosis
accounting for €242 million in costs. The most frequent
main diagnoses when diabetes was a secondary diagnosis
were cardiovascular diseases (31% of costs), malignancies
(12%) and respiratory diseases (11%). Of the secondary
diagnoses, type 2 diabetes (E11) accounted for 65%, while
type 1 (E10) accounted for 34%.
The diabetes related in-hospital costs per inhabitant
were 27% higher in the geographic region with the high-
est costs compared to region with the lowest when
accounting for admissions with diabetes as main and
secondary diagnosis. The total national in-hospital costs
would be €302 million if all regions had the same cost
level as the most costly, 15% more than the numbers
presented in Table 1.
Outpatient clinic visits
The costs related to outpatient clinic visits in hospitals
amounted to €7.9 million (included in Table 2).
Physician services
The cost of services from GPs and emergency units was
€14.4 million (Table 3) including home visits for hypo-
glycaemia. The cost relating to private practicing specia-
lists amounted to €2.5 million. On the basis of the
survey of persons with diabetes, the estimated annual
cost of physician home visits for hypoglycaemia was
€0.6 million (Table 4).
Table 1 Cost of in-hospital care according to diagnosis
Diabetes as main diagnosis Number of hospital
stays
Total
(million €)
Type 1 diabetes* 5 813 13.5
Type 2 diabetes ** 2 446 5.7
Other*** 625 1.7
Total cost - main diagnosis 8 884 20.9
Diabetes as secondary
diagnosis (ICD-10)
Number of hospital
stays
Total
(million €)
Infections (A00-A99+B00-B99) 1 686 9.3
Malignancies (C00-D89) 5 011 28.6
Neurological diseases (G00-G99) 1 401 4.2
Diseases of the eye (H00-H59) 1 405 2.3
Cardiovascular diseases (I00-I99) 14 545 74.2
Respiratory diseases (J00-J99) 4 504 25.8
Gastrointestinal diseases (K00-K93) 3 423 15.9
Musculoskeletal diseases (M00-
M99)
2 777 16.4
Urinary tract diseases (N00-N99) 3 518 16.1
Other*** 15 043 49.1
Total cost - secondary
diagnosis****
53 313 241.8
* ICD-10 code E10, Insulin-dependent diabetes mellitus
** ICD-10 code E11, Non-insulin-dependent diabetes mellitus
*** ICD-10 codes E23.2, H28, N08.3, O24, P70.0, P70.1, P70.2, R73.0, Z13.1
**** Of the secondary diagnosis type 2 diabetes (E11) accounted for 65
percent, while type 1 (E10) accounted for 34 percent.
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Drugs
The cost of hypoglycaemic agents for treating diabetes
was €49.6 million (17% of total costs) (Table 5) of which
€35.1 million (70%) represented insulin and analogues
(A10A) and the rest oral glucose lowering drugs (A10B).
Within the insulin group the cost of intermediate-acting
insulin (A10AC) was €15 million and fast-acting insulin
(A10AB) was €12.5 million. In the group of glucose
lowering drugs (A10B) the cost of sulphonamides, urea
derivatives (A10BB) was €6.2 million and biguanides
(A10BA) €4.7 million. For antihypertensive drugs the
estimated cost was €1.2 and €13.0 million for type 1 and
2 diabetes, respectively, while it was €2.4 and €28.3 for
cholesterol lowering drugs.
Medical equipment
Expenditure on diabetes related medical equipment was
€40 million (Table 6). The largest component here was
glucose tests accounting for €32 million (80% of the
total). Lancets for blood sampling accounted for
approximately €5.3 million, (13% of the total).
Other types of costs
Among costs estimated on the basis of the patient sur-
vey (Table 4), physiotherapy accounted for €18.8 mil-
lion, foot therapy €20.8 million, acupuncture €5.7
million and nutrition guidance €0.9 million.
Table 2 Total cost of diabetes in Norway 2005
Cost factor Cost (million €)
Direct
costs
In hospital care 20.9
Outpatient care 7.9
GP and emergency visits 14.4
Private practicing specialist services 2.6
Insulin and analogues (A10A*) 35.1
Oral glucose lowering drugs (A10B*) 14.5
Cholesterol lowering drugs 30.7
Antihypertensive drugs 14.2
Medical devices 40.1
Nutritionist guidance 0.8
Foot therapist 19.4
Physiotherapy 16.5
Acupuncture 5.3
Subtotal (76%)
222.4
Indirect
costs
Sickness compensation 16.6
Permanent disability pension and time limited
disability pension
48.2
Basic and/or supplemental benefits 5.3
Subtotal (24%)
70.1
Total 292.5
Table 3 Cost of physician services according to type of contact
Surgery visits
(million €)
Home visits
(million €)
Other contacts
(million €)
Total cost
(million €)
GPs and emergency units
Type 1 diabetes* 0.918 0.0349 0.1633 1.117
Type 2 diabetes ** 11.646 0.1600 1.4341 13.240
Other*** 0.044 0.0001 0.0104 0.054
Subtotal 12.608 0.1952 1.6078 14.411
Specialists in private practice
Type 1 diabetes**** 0.468 0.0000 0.0122 0.480
Type 2 diabetes***** 1.616 0.0007 0.0440 1.661
Retinopathy****** 0.156 — 0.0006 0.156
Retinopathy******* 0.180 — 0.0004 0.180
Other******** 0.069 0.0012 0.070
Subtotal 2.490 0.0007 0.0582 2.549
Total 15.098 0.1959 1.6660 16.960
* ICPC code T89, Insulin-dependent diabetes
** ICPC code T90, Non-insulin-dependent diabetes
*** ICPC codes F38 Retinopathy and W85 Diabetes during pregnancy
**** ICPC code T89 and ICD-10 code E10, Insulin-dependent diabetes
***** ICPC code T90 and ICD-10 code E11, Non-insulin-dependent diabetes
****** ICPC code F83 Retinopathy
******* ICD-10 code H36.0 Retinopathy
******** E23.2, H28.0, H36.0, N08.3, O24, P70.0, P70.1, P70.2, R73.0, Z13.1
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Indirect costs
The costs related to sick leave were €16.7 million
(Table 7) of which type 2 diabetes accounted for 85%.
Total costs related to time limited disability support and
disability pensions amounted to €48.2 million (Table 8),
of which disability pensions accounted for €46.4 million
(96%). Cost of basic and supplemental benefits was €5.3
million (Table 9).
Total costs
Total costs were €293 million (Table 2) when hospital
stays with diabetes as secondary diagnoses were
excluded and €535 million when they were included.
The largest component was medicines with €95 million
(32% of the total). The second largest was disability pen-
sions with €48 million (16%). Medical devices contribu-
ted €40 million (14%) and hospital admissions €21
million (7%).
Discussion
The results of this study clearly indicate that diabetes
places a financial burden on the persons with diabetes
themselves and furthermore the Norwegian public
health care system. The total costs of treating diabetes
in Norway in 2005 amounted to about €293 million or
1.4% of total health care expenditures [18], or 2.6% if all
diabetes related hospital stays are included. Interestingly,
patient expenditures for acupuncture, physiotherapy and
foot therapy were many times that of those for nutri-
tional guidance. In addition, diabetes imposes costs on
society in terms of lost production from job absenteeism
and premature mortality.
Cost-of-illness analyses in general should always be
viewed in the context of potential limitations: some
costs may be underestimated, some costs may be over-
estimated and some costs are omitted. Regarding our
study, we have not accounted for productivity losses
from diabetes-related premature mortality because we
adopted the prevalence approach. In addition, diabetes
may cause complications such as cardiovascular disease,
renal failure, retinopathy, erectile dysfunction and others
that incur costs. To the extent diabetes is stated as a
secondary diagnosis at hospital discharge, such costs are
included in the €535 million estimate. With respect to
Table 4 Costs of various other services*
Resource use Unit
cost (€)
per hour/
visit
Cost
(million €)
(95% CI)**
Type 1
diabetes
Hypoglycaemia - home
visit
69 0.3 (0.1 - 0.6)
Nutritionist guidance 21 0.1 (0.1 - 0.2)
Foot therapist 53 1.4 (0.9 - 2.1)
Physiotherapy 28 2.3 (1.2 - 3.4)
Acupuncture 35 0.4 (0.1 - 0.8)
Subtotal ——— 4.5
Type 2
diabetes
Hypoglycaemia - home
visit
69 0.3 (0.0 - 0.4)
Nutritionist guidance 21 0.8 (0.5 - 1.2)
Foot therapist 53 19.4 (17.5 -
22.0)
Physiotherapy 28 16.5 (11.3 -
21.3)
Acupuncture 35 5.3 (2.6 - 10.6)
Subtotal ——— 42.3
Total 46.8
* Data collected in the patient survey
** Confidence intervals based on bootstrapping
Table 5 Cost of hypoglycaemic agents, cholesterol
lowering drugs and antihypertensive drugs
Number of
users
Million
DDD
Costs*
(million €)
Insulin and analogues (A10A**)
***
47 073 28.9 35.1
Oral glucose lowering drugs
(A10B**)***
85 014 36.2 14.5
Cholesterol lowering drugs**** 85 880 — 30.7
Antihypertensive drugs**** 92 172 — 14.2
Total — — 94.5
* Costs in terms of prices in Pharmacy sales prices including VAT
** ATC code
*** Data from the National prescription database
**** Data from a patient survey
Table 6 Cost of medical devices
Reimbursement Patient
co-payment
Total
Costs
(million €)
Glucose tests 29.484 2.096 31.580
Lancets for blood
sampling
4.885 0.378 5.262
Injection catheter 0.01 0.00024 0.010
Insulin pens 0.44 0.036 0.476
Needles for insulin pens 2.394 0,182 2.576
Insulin syringe 0.105 0.008 0.113
Urine test sticks 0.040 0.003 0.043
Total 37.358 2.703 40.061
Table 7 Cost of sick leave due to diabetes
Diagnose
(ICPC)
Number of
patients
Days of
support
Payment
(million €)
Insulin-dependent (T89) 269 17 602 1.6
Non-insulin-dependent (T90) 2 593 156 706 14.1
Retinopathy (F83) 149 7 948 0.8
Diabetes during pregnancy (W85) 38 1 523 0.13
Total 3049 183 779 16.7
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some of the complications, there are many causal factors
and no reliable data on the fraction attributable to
diabetes.
When estimating the cost of in-hospital care on the
basis of the main diagnosis (Table 1), some hospitals
stays may be lost even when diabetes was the main cause
of the stay. Because hospitals in Norway have partial
DRG financing, the choice of primary diagnosis may be
influenced by the financial consequences of choice of pri-
mary diagnosis. The results of a Norwegian study [19]
indicate that diabetes patients tend to have higher costs
than the average patient within certain DRGs. To the
extent that this is the case, our estimates are biased.
A lack of diabetes diagnosis may also bias costs related to
disability pensions and sick leave, physician visits, outpa-
tient clinic visits and certain other types of services
where the costing is based on diagnosis. Finally, costs
based on patient reported use of care may be underesti-
mated because patients do not recall all use of care.
When including in-hospital care for stays where diabetes
was a secondary diagnosis (Table 1), some stays may not
be caused in full by diabetes. If for example diabetes is sta-
ted as secondary diagnosis for a patient discharged from
hospital because of a malignant disease, at most a minority
of the costs may be attributable to diabetes.
Costs of hypoglycaemic agents stems from the
national prescription database and contain all prescrip-
tions redeemed in pharmacies. Costs related to drugs
provided in hospitals are included in the DRG reimbur-
sement to hospitals. Pharmaceuticals used to prevent or
treat diabetes related complications are difficult to quan-
tify, but lipid lowering and antihypertensives are
included on the basis of the patient survey.
The NLWA keeps account of reimbursement for dia-
betes related medical devices and these costs are likely
to be complete. Also, drug costs are quite accurate
because all pharmacies register prescriptions electroni-
cally and transfer their data to the central registry.
We have included some types of costs that we con-
sider relevant for persons with diabetes, such as doctor
home visits related to hypoglycaemia, nutritionist gui-
dance, foot therapy, physiotherapy and acupuncture. We
can not attribute all costs gathered in the patient survey
to diabetes. For example, there are reasons other than
diabetes for having acupuncture. It should be noted that
the survey we undertook may not be entirely representa-
tive of the diabetes population in Norway, especially for
type 2 diabetes. Some cost estimates (GP home visits for
hypoglycaemia, foot therapy, nutritional guidance, phy-
siotherapy, acupuncture, costs of cholesterol lowering-
and antihypertensive drugs) may consequently be biased,
but the impact on any bias will be small because the
relevant costs were small.
Our study provides some important general lessons
about the cost structure of diabetes care. First, the
main direct cost-drivers from diabetes are hospital
services, pharmaceuticals and medical devices. These
services are reimbursed in part or in full by govern-
ments in most industrialised countries. Second, other
types of services such as foot therapy, physiotherapy,
and acupuncture may represent considerable costs, but
often receive only partial and sometimes no reimburse-
ment by governments. In Norway, the use of foot ther-
apy is paid in full by the patient, while in contrast the
cost of foot ulcer treatment and amputations is cov-
ered almost fully by the government. This may seem
paradoxical as untreated foot ulcers may lead to infec-
tions and ultimately amputation. Finally, the study
reveals a high level of spending on acupuncture com-
pared to much lower spending on nutritional guidance.
Given the importance of diet for the progress of the
disease, this result is somewhat paradoxical and sug-
gests that patients could benefit from a different
spending pattern.
We found that hospital costs with diabetes as main
diagnosis were twice as high for type 1 diabetes as for
type 2. However, a large proportion of those with non-
insulin-dependent diabetes had CVD as the primary
diagnosis. Diabetes is likely an important causal factor
for CVD among these patients which indicates that type
2 diabetes still is a major cost driver. It is therefore
likely that type 2 diabetes is more important than type 1
diabetes with respect to hospital costs.
The number of individuals on oral glucose lowering
drugs was almost twice the number of users of insulin
and analogues. In terms of costs, the pattern was oppo-
site in that the total cost of insulin and analogues was
twice the cost of oral glucose lowering drugs. This indi-
cates that treatment of type 2 diabetes becomes more
Table 8 Cost of disability pension and time limited
disability pension related to diabetes
Benefit (€) Number of
patients
Expenditure
(million €)
Time limited disability support 17 250 112 1.9
Disability pension 16 689 2 775 46.4
Total 16 711 2 887 48.2
Table 9 Basic and supplemental benefits related to
diabetes*
Number of
patients
Expenditure
(million €)
Basic benefits 1058 1.4
Supplemental benefits 1876 3.9
Total 2934 5.3
* Approximately 15% of overall receivers of basic and supplemental benefits
are lacking diagnosis in the database
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costly with disease progression because insulin is
increasingly prescribed with progression.
Our results are somewhat different from those
reported elsewhere. In Sweden the estimated costs of
hypoglycaemia related to type 2 diabetes was €14.10 per
patient per year [20] while our data would suggest about
€3 per patient. The Swedish costs are higher because of
a higher reported prevalence of hypoglycaemia and the
inclusion of indirect costs.
One should be aware of methodological differences
when comparing the results of cost-of-illness analyses.
We used a prevalence approach; studies relying on an
incidence approach with prediction of future costs may
yield higher values. Also, the method for valuing
absence from productive work may have considerable
impact on the results of cost-of-diabetes studies. Clearly,
the more types of diabetes related costs that are
included, the higher the estimated costs. A recent review
[21] suggests that there is a general tendency for indir-
ect costs to make up a slightly larger proportion of total
costs than direct costs. In the studies reviewed, the pro-
portion of indirect costs was in the range of 25-64%.
A study performed in Ireland [22] estimated that the
costs of treating diagnosed type 2 diabetes was 4.1% of
the total health care expenditure. Hospitalisations
accounted for almost half of overall costs, while ambula-
tory and medicines costs accounted for 27% and 25%.
In an early Swedish [3] study, the costs of diabetes
amounted to 5.7 billion Swedish Kroner (SEK) (€570 mil-
lion) of which 43% represented direct costs. Hospital care
estimates were based on the main diagnosis and repre-
sented the main component of direct costs. The distribu-
tion among the different types of direct costs were about
the same in the Swedish study as our. The indirect costs
in the Swedish study represented 57% of the total com-
pared to 24% in our study when including only hospital
admissions with diabetes as the main diagnosis. This dif-
ference is in part attributable to the fact the Swedish
study included productivity losses caused by premature
mortality while ours did not. Whether the remaining dif-
ference between the two studies is attributable to differ-
ence in time or difference in real costs is unclear.
In a recent Swedish study [23] which report increasing
costs of diabetes over time, another approach to COI
analysis is used. Diabetes prevalence and attributable
risks for diabetes complications were used to estimate
the diabetes-related costs. This approach should result
in an estimate of the COI that is between estimates
based on diabetes as the primary diagnosis and esti-
mates based on diabetes as the primary as well as the
secondary diagnosis.
The wide variation in methodology makes comparison
of the results difficult and calls for standardisation of
methods. Patient organisations might play a role in
developing guidelines for COI studies. Additionally,
there is a need for more research into how choice of
methods impact the results using data from the same
country and the same time rather than comparing
across countries. Even though COI represent a basis for
allocating research resources, most research should be
directed at studies of intervention effectiveness and how
care can be provided in the most efficient way. The lat-
ter in practice means cost-effectiveness studies, and our
COI study could be used as a toolbox for analysts in
need of cost data. If later studies are performed in the
same way, it may provide useful insight in how costs
develop over time.
Conclusions
In conclusion, the cost of diabetes represents 1.4% -
2.6% of the total health care expenditures in Norway,
depending on how diabetes related hospitalisation is
accounted for. The high diabetes costs indicate that
society may do well in devoting resources to diabetes
prevention and research.
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Health-related quality of life in diabetes: The
associations of complications with EQ-5D scores
Oddvar Solli1*, Knut Stavem2,3, IS Kristiansen1,4
Abstract
Background: The aim of this study was to describe how diabetes complications influence the health-related
quality of life of individuals with diabetes using the individual EQ-5D dimensions and the EQ-5D index.
Methods: We mailed a questionnaire to 1,000 individuals with diabetes type 1 and 2 in Norway. The questionnaire
had questions about socio-demographic characteristics, use of health care, diabetes complications and finally the
EQ-5D descriptive system. Logistic regressions were used to explore determinants of responses in the EQ-5D
dimensions, and robust linear regression was used to explore determinants of the EQ-5D index.
Results: In multivariate analyses the strongest determinants of reduced MOBILITY were neuropathy and ischemic
heart disease. In the ANXIETY/DEPRESSION dimension of the EQ-5D, “fear of hypoglycaemia” was a strong
determinant. For those without complications, the EQ-5D index was 0.90 (type 1 diabetes) and 0.85 (type 2
diabetes). For those with complications, the EQ-5D index was 0.68 (type 1 diabetes) and 0.73 (type 2 diabetes). In
the linear regression the factors with the greatest negative impact on the EQ-5D index were ischemic heart disease
(type 1 diabetes), stroke (both diabetes types), neuropathy (both diabetes types), and fear of hypoglycaemia (type 2
diabetes).
Conclusions: The EQ-5D dimensions and the EQ-5D seem capable of capturing the consequences of diabetes-
related complications, and such complications may have substantial impact on several dimensions of health-related
quality of life (HRQoL). The strongest determinants of reduced HRQoL in people with diabetes were ischemic heart
disease, stroke and neuropathy.
Background
Diabetes is a chronic disease with serious short-term
and long-term consequences for the afflicted. The total
number of individuals with diabetes worldwide is pro-
jected to rise from about 170 million in 2000 to about
370 million in 2030 [1]. In the long term, diabetes
causes microvascular complications (e.g. retinopathy and
neuropathy) and macrovascular complications (e.g. myo-
cardial infarction, angina pectoris and stroke). In addi-
tion to diabetes-related complications, episodes of
hypoglycaemia, fear of hypoglycaemia, change in life
style and fear of long term consequences may lead to
reduced health-related quality of life (HRQoL). In fact,
individuals with diabetes have reduced HRQoL com-
pared with those without diabetes in the same age
group [2,3], and their HRQoL decreases with disease
progression and complications [4,5].
There are three main approaches to describe and mea-
sure HRQoL: Disease-specific instruments, generic instru-
ments and utility instruments. Numerous disease-specific
HRQoL measures exist for diabetes, and these score
HRQoL on ordinal scales [6-8]. Generic instruments such
as the Short Form 36 (SF-36) are also used [9]. In multi-
attribute utility instruments (MAU), such as the EQ-5D
[10], 15D [11], Health Utility index (HUI) [12,13] and SF-
6D [14], respondents indicate levels of health problems on
a number of dimensions of health. These values are trans-
lated into a zero-one scale where zero denotes death and
one perfect health. Some utility instruments allow for
negative values, meaning that some health states are con-
sidered worse than death. Preference-based methods such
as the time trade-off method (TTO) [15], standard gamble
(SG) or the visual analogue scale (VAS) may be used to
develop translation algorithms. When the HRQoL weight
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is multiplied with duration (years, months, duration of
effect, expected remaining life years) the product is
denoted QALY (quality-adjusted life years) [16]. QALYs
can be calculated for different patient groups to compare
for example effectiveness of treatment, enabling health
improvements and life extensions to be captured in one
single variable.
EQ-5D [10] is a MAU instrument with five dimen-
sions (MOBILITY, SELF-CARE, USUAL ACTIVITIES,
PAIN/DISCOMFORT and ANXIETY/DEPRESSION)
and three levels on each dimension, and has previously
been used in populations with diabetes [17]. EQ-5D has
been used extensively in economic evaluation, and is
recommended for use in cost-effectiveness analyses by
institutions such as the National Institute for Clinical
Excellence (NICE) in the UK and the Health Care Insur-
ance Board in the Netherlands. Therefore, researchers
working with economic evaluation, government agencies
and the pharmaceutical industry need easy access to uti-
lity data for different types of patients.
Against this background the aim of this study was
three-fold:
• To use the five individual EQ-5D dimensions to
describe some aspects of HRQoL in a group of peo-
ple with diabetes.
• To investigate the impact of self-reported diabetes-
related complications on the EQ-5D dimension
scores.
• To investigate determinants of EQ-5D index in
order to offer researchers utility data for individuals
with diabetes.
Methods
The data in this study stem from a Norwegian survey of
people with diabetes in 2006. A questionnaire was devel-
oped and piloted among health care professionals,
including physicians with diabetes expertise and the
county leaders of the Norwegian Diabetes Association
(NDA). The latter group served as representatives of the
target group. The study was approved by the Regional
Ethics Committee and the Norwegian Data Inspectorate.
The seven-page questionnaire captured background
variables such as age, gender, location, income in Nor-
wegian Kroner (NOK), smoking habits, height, weight,
as well as diabetes-specific variables such as diabetes-
related health complications and use of health services.
Finally, respondents were presented with eight diabetes-
specific HRQoL questions and an approved Norwegian
translation of the EQ-5D descriptive system. EQ-5D
responses were translated into EQ-5D index utilities
using the UK TTO tariff [18].
The questionnaire was mailed to a sample of members
of the Norwegian Diabetes Association. A large
proportion of the individuals with type 1 diabetes in
Norway are members of the NDA, while only a minority
of those with type 2 diabetes are members. After exclud-
ing individuals under the age of 18 years and those
without diabetes, such as health care workers and others
with an interest in diabetes, the NDA drew a random
sample of 1,000 members. Non-respondents were fol-
lowed up twice. The last follow up was accompanied by
a letter from the NDA explaining the importance of
insight in diabetes and encouraging response.
Data analyses
For descriptive statistics, we used means, proportions
and standard deviations. Determinants of EQ-5D dimen-
sion values were analysed by logistic regression. For all 5
dimensions level 2 and 3 on the EQ-5D dimensions
were merged and thus dichotomized to “no problem” or
“some or extreme problem”. We performed separate
regressions for type 1 and type 2 diabetes.
The EQ-5D index was analysed with a linear OLS
regression model. The Breusch-Pagan test and plotting
residuals versus fitted values showed that heteroscedasti-
city was present both for type 1 and type 2 diabetes.
Therefore, we applied White’s robust variance
estimators.
The data were complete except for the covariates
“Fear of hypoglycaemia” (13% missing), “Limitations at
work” (23% missing) and “Limitations socially” (10%
missing). Missing values were therefore imputed with
regressions based on 15 independent variables (sex, age,
weight, height and 11 diabetes-related complications).
We used the impute function in STATA, which runs
regressions by simple best-subset linear regression, look-
ing at the pattern of missing values in the predictors.
We tested the covariates age and body mass index
first as dummy variables divided in quartiles and second
as continuous variables.
We chose covariates for the models based on input
from health care professionals and representatives from
academia. In the binary regressions the selected vari-
ables are considered plausible to be linked with the
dimension analysed. In addition to “Sex” and “age”, all
direct medical complications were included in all
dimensions except “Proteinuria”. We believe this covari-
ate is likely only to remind the individuals of lurking
complications and should thus only impact the ANXI-
ETY/DEPRESSION dimension. The variable “Impaired
vision” is in our view not likely to directly cause pain or
discomfort and is not included in regression of the
PAIN/DISCOMFORT dimension. Emotional impact of
impaired vision should be captured in the ANXIETY/
DEPRESSION dimension.
In both the logistic binary and the linear regressions
full sets of the selected covariates were kept throughout
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the analysis in order to provide variables with both sig-
nificant and non-significant impact on the covariates.
For the linear regression this would provide a full set of
results which may be used by other analysts in decision
analytic modelling.
All analyses were performed in STATA/SE 10.0 (Stata
Corp, College Station, TX, USA).
Results
Sample characteristics
Of the total 1,000 eligible individuals with diabetes, 17
were excluded because they had died (n = 4) or had
unknown address (n = 13). Two persons declined to
participate. In total 598 of those eligible returned the
questionnaire, of which 521 were complete and could be
used in further analysis (response rate 53%). Among
non-respondents, 51% were female compared with 47%
among respondents.
Among the 521 respondents, 165 reported having type
1 diabetes (53% female), and 356 type 2 diabetes (44%
female) (Table 1). Further descriptive statistics about
demographics, risk, factors for complications, medica-
tion and complications are shown in Table 1.
Health-related quality of life
In total 10% of those with type 1 diabetes had problems
with MOBILITY as judged from the EQ-5D, 3% with
SELF-CARE, 19% with USUAL ACTIVITIES, 34% with
PAIN/DISCOMFORT and 35% with ANXIETY/
DEPRESSION (Table 2). For Type 2 diabetes the num-
bers were 26%, 6%, 25%, 45% and 33%, respectively. The
mean EQ-5D index score was 0.83 (SD 0.24) in type 1
diabetes and 0.81 (SD 0.22) in type 2 (p = 0.32). The
proportion of type 2 diabetes patients with fear of hypo-
glycaemia was 50% among those on insulin and 26%
among the others.
For individuals without any reported complications,
the mean EQ-5D index scores were 0.90 for those with
type 1 diabetes and 0.85 for those with type 2 (Table 3).
The presence of one complication decreased values to
0.76 and 0.80, respectively. With two or more diabetes-
related complications the values were 0.55 and 0.64,
respectively.
Regression analyses
In the binary logistic regressions of type 1 diabetes on
EQ-5D dimension responses (Table 4), ischemic heart
disease, foot ulcer, neuropathy, body mass index and
receiving help from others were statistically significant
determinants for reporting problems in the MOBILITY
dimension. None of the covariates had impact on the
SELF-CARE dimension. Disability pension and limita-
tions at work had an impact on the USUAL ACTIV-
ITIES dimension. Age, ischemic heart disease and
neuropathy had an impact on the PAIN/DISCOMFORT
dimension, and age, impaired vision, ischemic heart dis-
ease, neuropathy and fear of hypoglycaemia had an
impact on the ANXIETY/DEPRESSION dimension.
For type 2 diabetes (Table 5), age, impaired vision,
stroke, neuropathy, body mass index and receiving help
from others were statistically significant determinants of
MOBILITY. Receiving help from others for SELF-CARE,
sex, stroke, disability pension, receiving help from others
Table 1 Characteristics of the respondents according to
diabetes type, number (%), unless otherwise specified
Type 1 Type 2
n 165 356
Demographics
Sex, female 87 (53) 157 (44)
Age, mean (SD) 47.0
(14.9)
64.0
(11.7)
Annual family income (1000 NOK), mean (SD) 666 (908) 713
(3051)
Complication risk factors
Diabetes duration (years), mean (SD) 22.1
(14.2)
10.0 (8.1)
Current smoking 47 (29) 62 (18)
Daily smoker 22 (14) 42 (12)
Occasional smoker 25 (15) 20 (6)
Previous smokers 86 (55) 200 (61)
Body mass index, kg/m2 , mean (SD) 25.8 (4.8) 28.9 (5.1)
Medication
Number of oral antidiabetic agents
0 159 (96) 103 (29)
1 4 (2) 149 (42)
2 2 (1) 87 (24)
3 — 16 (5)
4 — 1 (0.3)
Insulin
Short-acting insulin 152 (92) 68 (19)
Long-acting insulin 103 (62) 98 (28)
Insulin glargine (Lantus) or insulin detemir
(Levemir)
51 (31) 11 (3)
Antihypertensives 52 (33) 217 (63)
Cholesterol lowering drug 45 (28) 205 (59)
Self-reported complications
Impaired vision 31 (19) 51 (14)
Myocardial infarction 4 (2) 38 (11)
Angina 10 (6) 27 (8)
Reduced kidney function (Proteinuria) 15 (9) 24 (7)
Kidney transplant 1 (1) 2 (1)
Foot ulcer 6 (4) 13 (4)
Amputation 2 (1) 1 (0.3)
Stroke 5 (3) 19 (5)
Neuropathy 12 (7) 17 (5)
Other 37 (22) 53 (15)
None 79 (47) 161 (45)
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and limitations at work were associated with USUAL
ACTIVITIES. Ischemic heart disease, neuropathy and
hypoglycaemia had an impact on PAIN/DISCOMFORT.
Age, foot ulcers, number of hospital admissions during
the previous 6 months and fear of hypoglycaemia were
associated with ANXIETY/DEPRESSION scores.
In the linear regression of the EQ-5D index for type 1
diabetes, presence of ischemic heart disease had a nega-
tive impact (-0.181), along with stroke (-0.291), neuropa-
thy (-0.358), receiving disability pension (-0.111) and
social limitations (-0.107) (Table 6). For type 2 diabetes
the following conditions had a negative impact (Table
6): stroke (-0.135), neuropathy (-0.187), disability pen-
sion (-0.100), receiving help from others (-0.123), fear of
hypoglycaemia (-0.078) and limitations at work (-0.087).
For both diabetes types we tested for interactions, but
found none. We found no effect of age or body mass
index in the linear regressions whether age and BMI
were entered as one continuous variable or as dummy
variables.
Discussion
In this study, individuals with diabetes-related complica-
tions had reduced HRQoL, though the impact on
HRQoL was somewhat different for type 1 and type 2
diabetes. Stroke and neuropathy had a negative impact
on overall HRQoL in both types of diabetes, while
ischemic heart disease and social limitations had an
impact on those with type 1 diabetes, and fear of hypo-
glycaemia and limitations at work had an impact on
those with type 2 diabetics. Individuals with type 1 dia-
betes reported more problems than those with type 2 in
the PAIN/DISCOMFORT and ANXIETY/DEPRESSION
dimensions, while in the MOBILITY, SELF-CARE and
USUAL ACTIVITIES dimensions it was opposite. In
spite of the limited descriptive system of the EQ-5D, the
instrument still captures the impact of several diabetes
complications both with respect to each of the dimen-
sions and the EQ-5D index, and therefore individual
EQ-5D dimensions seem well suited to capture most
diabetes-related complications.
In a 2009 review of quality of life measurement in
adults with diabetes [19] the authors claim that the EQ-
5D measures quality of health and not quality of life
and that the EQ-5D lacks responsiveness for use in dia-
betes. The authors state that while the EQ-5D may cap-
ture differences due to diabetes related complications it
will not necessarily be able to capture differences across
treatment regimens. This is because the extent to which
a given treatment is considered flexible or convenient
will not affect quality of health but may affect aspects of
quality of life, such as social or working life. The
authors suggest using diabetes-specific instruments or a
different generic instrument more sensitive to differ-
ences between treatments. Our results show that while
both the individual dimensions of the EQ-5D and the
EQ-5D index are able to capture typical diabetes-related
complications, the subgroups without complications
reported surprisingly high EQ-5D index values. This
may indicate that the EQ-5D instrument was not able to
capture important non-health aspects of quality of life,
as claimed in the review [19]. Because the EQ-5D
instrument is not diabetes specific, lowered scores may
reflect the impact of unrelated comorbidity. A condition
specific instrument such as the ADDQoL may differenti-
ate better between diabetes related complications and
unrelated comorbidity [19].
In the present study, the finding that individuals with
type 1 diabetes reported better HRQoL than those with
type 2 can be explained by the younger age of the for-
mer group. The opposite was observed in subgroups
with complications, and it seems as if diabetic complica-
tions had more impact on HRQoL in type 1 diabetes
than type 2. A possible explanation is that complications
Table 2 Distribution of levels of perceived problem in
each of the dimensions of the EQ-5D descriptive system,
according to diabetes type
Type 1 (n = 165) Type 2 (n = 356)
Level of perceived problem, %
Dimension 1* 2* 3* 1* 2* 3*
Mobility 90 10 0 74 26 0
Self-care 97 3 0 94 6 0
Usual activities 81 18 1 74 24 1
Pain/discomfort 65 29 5 56 41 4
Anxiety/depression 65 32 3 67 30 3
* Level 1 implies no problem, 2 moderate problem, 3 severe problem
Table 3 Mean EQ-5D index utility values with and without diabetes-related complications
Type 1 diabetes Type 2 diabetes
Number of complications EQ-5D index 95% CI n EQ-5D index 95% CI n
0 0.90 0.88 - 0.93 111 0.85 0.82 - 0.87 241
1 0.76 0.66 - 0.86 35 0.80 0.75 - 0.85 68
≥ 2 0.55 0.37 - 0.73 19 0.64 0.56 - 0.71 47
Any complication 0.68 0.59 - 0.77 54 0.73 0.69 - 0.78 115
All patients 0.83 0.79 - 0.87 165 0.81 0.79 - 0.83 356
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are likely to have a greater impact on the health of peo-
ple with type 1 diabetes precisely because they are
younger, i.e. have less comorbidity and have not
adjusted to the idea of accepting lesser health. The dif-
ferences could also be explained by the fact that this
younger subgroup has responsibilities such as work and
family as well as relationship issues that are not found
in the older subgroup with type 2 diabetes.
In the UKPDS 37 study [20] individuals with type 2
diabetes and no complications had a mean EQ-5D index
value of 0.83, compared with 0.85 in our study. In type
2 diabetes with complications, our observed EQ-5D
index value (0.73) was equal to that of the UKPDS 37
study. Taking into account that patient characteristics
were similar in the UKPDS and our study, UK diabetes
studies may be transferable to the Norwegian setting. In
the UKPDS 37 study the EQ-5D detected significant dif-
ferences between people with and without
macrovascular complications, but not microvascular
complications or using different treatment regimens. In
our study the microvascular complication neuropathy
had impact on the individual EQ-5D dimensions and on
the EQ-5D index.
In another UK study [21] of individuals with type 2
diabetes, the change in utility associated with fear of
hypoglycaemia was relatively small compared with the
disutility for serious diabetic complications such as neu-
ropathy. Similarly, in our study fear of hypoglycaemia
caused a reduction in utility of 0.021 (type 1 diabetes)
and 0.078 (type 2), while the disutility of neuropathy
was larger with 0.358 (type 1 diabetes) and 0.187 (type 2
diabetes). We have no clear explanation why our results
indicate a lower impact on HRQoL of fear of hypogly-
caemia in individuals with type 1 diabetes than those
with type 2 diabetes. Fear of hypoglycaemia may not
affect HRQoL particularly (e.g. has little impact on pain
Table 4 Binary multivariate logistic regression of responses to the EQ-5D items in type 1 diabetics, odds ratios (95%
CI)
EQ-5D dimensions
Mobility Self-care Usual activities Pain/discomfort Anxiety/
depression
Sex (male = 0, female = 1) 0.63 (0.14 - 2.74) 0.25 (0.01 - 5.15) 0.67 (0.22 - 2.03) 0.45 (0.20 - 1.03) 1.12 (0.50 - 2.51)
Age (in 10 years) 1.33 (0.78 - 2.25) 1.37 (0.55 - 3.43) 0.93 (0.61 - 1.40) 1.36 (1.04 - 1.77)* 0.72 (0.55 - 0.94)*
Impaired vision (no = 0, yes = 1) 3.00 (0.53 - 16.85) 12.11 (0.49 -
297.88)
0.28 (0.07 - 1.15) ——— 4.60 (1.57 - 13.46)
**
Ischemic heart disease (no = 0, yes = 1) 11.72 (2.02 -
68.09)**
1.24 (0.05 -
31.42)
4.15 (0.73 - 23.64) 5.84 (1.29 - 26.40)* 6.82 (1.34 - 34.75)
*
Proteinuria (no = 0, yes = 1) ——— ——— ——— ——— 0.47 (0.09 - 2.47)
Foot Ulcer (no = 0, yes = 1) 13.33 (1.33 -
133.29)*
6.20 (0.17 -
221.73)
10.04 (0.80 -
126.22)
3.24 (0.47 - 22.43) 1.06 (0.16 - 6.96)
Stroke (no = 0, yes = 1) 0.47 (0.02 - 8.99) 17.37 (0.49 -
610.92)
1.24 (0.09 - 16.83) 10.66 (0.75 -
152.16)
1.14 (0.13 - 10.21)
Neuropathy (no = 0, yes = 1) 7.17 (1.22 - 42.03)
*
5.86 (0.41 -
83.43)
6.96 (1.45 - 33.44) 27.13 (3.13 -
235.07)**
4.61 (1.05 - 20.21)
*
Body mass index (kg/m2 ) 1.15 (1.02 - 1.30)* ——— ——— ——— ———
Disability pension (no = 0, yes = 1) ——— ——— 4.64 (1.33 - 16.18)* ——— ———
Number of hospital admissions during previous 6
months
——— ——— ——— ——— 1.22 (0.58 - 2.53)
Receives help from others (no = 0, yes = 1) 10.04 (2.03 -
49.69)**
10.28 (0.61 -
173.34)
1.90 (0.50 - 7.22) ——— ———
Hypoglycaemia index# ——— ——— ——— 1.59 (0.87 - 2.89) 1.29 (0.71 - 2.33)
Fear of hypoglycaemia## (small = 0, large = 1) ——— ——— ——— ——— 3.98 (1.78 - 8.93)
**
Limitations at work## (small = 0, large = 1) ——— ——— 13.20 (3.38 -
51.53)***
——— ———
Limitations socially## (small = 0, large = 1) ——— ——— 1.87 (0.65 - 5.37) ——— ———
Log likelihood -28.08 -9.96 -51.46 -85.06 -85.30
* p < 0.05, **p < 0.01, ***p < 0.001
Cells with dotted line indicate that the variable was not included in the model.
# Self reported episodes of hypoglycaemia, with 4 levels of severity (level 1 = hypoglycaemia cured with the intake of for example fluids containing sugar, no
help from other required, level 2 = hypoglycaemia cured with the intake of for example fluids containing sugar, help from others required, level 3 =
hypoglycaemia with help from doctor required (no hospital admission), level 4 = hypoglycaemia resulting in hospital admission), then added with severity
weights (level 1 × 1, level 2 × 2, level 3 × 3, level 4 × 4) and finally divided in 3 groups 0, 1-11 and 12 to max
## Self reported on a scale from 1 to 5 (1 = not at all, 5 = very much), recoded to 2 levels (> and < than 2.5 due to imputed values having values with decimals)
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or mobility) but it can affect aspects of more general
quality of life (e.g. independence, spontaneity, ability to
work, enjoyment of leisure activities).
In a US review [22] of body weight and HRQoL in
type 2 diabetes, the authors found decreasing HRQoL
with increasing body weight in all included studies.
When adjusting for other explanatory variables, we
observed no significant impact of BMI on HRQoL.
A subgroup of individuals with unspecified type dia-
betes (n = 117) in a Swedish general population EQ-5D
study [23], also using the UK tariff, reported a higher
frequency of problems in all dimensions of the EQ-5D,
than in both diabetes categories in our study. Further,
the respondents in the study reported a lower mean
EQ-5D index (0.74) than we observed in both type 1
and type 2 diabetes.
Some limitations of the present study should be noted.
The respondents in the survey may not be representa-
tive of the population with diabetes. In particular, bias
may arise because sicker and older persons with type 2
diabetes did not respond to the survey. A large propor-
tion of individuals with type 1 diabetes in Norway
(about 20,000) are members of the NDA while only a
smaller proportion of the type 2 (about 100,000) are
members of this organization. Clearly, our study does
not capture HRQoL in undiagnosed diabetes patients. In
Table 5 Binary multivariate logistic regression of responses to the EQ-5D items in type 2 diabetics, odds ratios (95%
CI)
EQ-5D dimensions
Mobility Self-care Usual activities Pain/
discomfort
Anxiety/
depression
Sex
(male = 0, female = 1)
0.68 (0.38 - 1.21) 0.59 (0.23 - 1.54) 0.47 (0.25 - 0.88)* 0.82 (0.53 -
1.27)
0.91 (0.54 - 1.52)
Age
(in 10 years)
1.36 (1.03 - 1.80)* 0.83 (0.55 - 1.25) 1.34 (1.00 - 1.80) 1.03 (0.83 -
1.24)
0.78 (0.62 - 0.99)*
Impaired vision
(normal = 0, reduced = 1)
2.96 (1.44 - 6.10)** 2.29 (0.77 - 6.75) 0.89 (0.39 - 2.04) ——— 1.46 (0.71 - 3.01)
Ischemic heart disease (no = 0, yes = 1) 1.97 (0.91 - 4.25) 1.77 (0.54 - 5.86) 1.14 (0.48 - 2.71) 2.51 (1.27 -
4.97)**
1.15 (0.53 - 2.50)
Proteinuria (no = 0, yes = 1) ——— ——— ——— ——— 0.42 (0.14 - 1.29)
Foot Ulcer (no = 0, yes = 1) 0.32 (0.07 - 1.39) 0.73 (0.11 - 4.67) 2.11 (0.48 - 9.39) 2.18 (0.54 -
8.79)
7.00 (1.53 - 31.97)
*
Stroke (no = 0, yes = 1) 3.50 (1.13 - 10.82)* 1.45 (0.23 - 9.13) 4.48 (1.38 -
14.59)*
1.99 (0.72 -
5.54)
2.14 (0.69 - 6.62)
Neuropathy (no = 0, yes = 1) 12.07 (3.30 - 44.12)
***
2.74 (0.57 - 13.25) 3.08 (0.84 -
11.26)
Predicts
perfectly#
1.29 (0.40 - 4.16)
Body mass index (kg/m2 ) 1.12 (1.05 - 1.19)
***
——— ——— ——— ———
Disability pension (no = 0, yes = 1) ——— ——— 2.38 (1.20 - 4.69)* ———
Number of hospital admissions during previous 6
months
——— ——— ——— ——— 1.87 (1.14 - 3.07)*
Receives help from others (no = 0, yes = 1) 5.85 (3.00 - 11.38)
***
6.95 (2.58 - 18.73)
***
4.67 (2.21 - 9.87)
***
——— ———
Hypoglycaemia index## ——— ——— ——— 1.68 (1.13 -
2.49)*
1.08 (0.70 - 1.68)
Fear of hypoglycaemia### (small = 0, large = 1) ——— ——— ——— ——— 5.76 (3.36 - 9.87)
***
Limitations at work### (small = 0, large = 1) ——— —— 6.95 (3.56 -13.56)
***
——— ———
Limitations socially### (small = 0, large = 1) ——— —— 1.33 (0.67 - 2.62) ——— ———
Log likelihood -156.08 -66.13 -136.85 -232.10 -187.32
* p < 0.05, **p < 0.01, ***p < 0.001
# All patients reporting neuropathy also reports having problems in the PAIN/DISCOMFORT dimension of the EQ-5D.
Cells with dotted line indicate that the variable was not included in the model.
## Self reported episodes of hypoglycaemia, with 4 levels of severity (level 1 = hypoglycaemia cured with the intake of for example fluids containing sugar, no
help from other required, level 2 = hypoglycaemia cured with the intake of for example fluids containing sugar, help from others required, level 3 =
hypoglycaemia with help from doctor required (no hospital admission), level 4 = hypoglycaemia resulting in hospital admission), then added with severity
weights (level 1 × 1, level 2 × 2, level 3 × 3, level 4 × 4) and finally divided in 3 groups 0, 1-11 and 12 to max
### Self reported on a scale from 1 to 5 (1 = not at all, 5 = very much), recoded to 2 levels (> and < than 2.5 due to imputed values having values with
decimals)
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line with other patient surveys, we had 47% non-
response. We have no information on non-respondents
except for sex (based on non-respondents first names),
and here there was little difference between responders
and non-responders.
It is important to be aware that because the EQ-5D
instrument is no diabetes specific it may reflect pro-
blems related to other conditions. Our study was per-
formed at one point in time, and fluctuations are likely
to occur if HRQoL was measured at multiple points in
time. The observed associations are not necessarily cau-
sal. Further they are limited by the lack of serial obser-
vations. Furthermore, the limited sample size, especially
for type 1 diabetes may limit the power for some of the
comparisons of presence or absence of complications.
Note that despite the index score being a function of
the score in the dimensions a significant impact on lin-
ear regression of the index does not necessarily imply a
significant impact on one or more of the dimensions.
This is the case for the covariate “stroke” which is sig-
nificant in both types of diabetes in the linear regression
by not significant in any of the dimensions in the type 1
diabetes group.
Lacking a Norwegian EQ-5D tariff we used the UK
tariff, based on TTO [18]. This tariff is probably the
most commonly used EQ-5D tariff globally, and quite
similar to the Danish one [24]. Also, one small
Norwegian study indicates that UK and Norwegian
values are quite similar [25].
Conclusions
In this sample of people with diabetes, the individual
EQ-5D dimensions were able to capture diabetes-related
complications. The results show that such complications
may have an impact on many dimensions of health-
related quality of life, and the impact may be substantial.
The strongest determinants of reduced HRQoL, as
assessed with the EQ-5D index, were ischemic heart dis-
ease, stroke and neuropathy. The complexity of the dis-
ease means that several dimensions need to be
considered when priorities are set for diabetes
interventions.
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Number of hospital admissions during previous 6 months 0.003 (-0.042 to 0.049) 0.880 -0.028 (-0.076 to 0.020) 0.255
Receives help from others (no = 0, yes = 1) -0.090 (-0.217 to 0.037) 0.166 -0.123 (-0.185 to -0.060) <0.001
Hypoglycaemia index# -0.023 (-0.071 to 0.025) 0.337 -0.004 (-0.039 to 0.032) 0.839
Fear of hypoglycaemia## (small = 0, large = 1) -0.021 (-0.073 to 0.031) 0.432 -0.078 (-0.129 to -0.028) 0.003
Limitations at work## (small = 0, large = 1) -0.023 (-0.089 to 0.043) 0.494 -0.087 (-0.148 to -0.025) 0.006
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weights (level 1 × 1, level 2 × 2, level 3 × 3, level 4 × 4) and finally divided in 3 groups 0, 1-11 and 12 to max ## Self reported on a scale from 1 to 5 (1 = not at
all, 5 = very much), recoded to 2 levels (> and < than 2.5 due to imputed values having values with decimals)
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Appendix 1 
English translation of the questionnaire used in the survey (Paper I and II) 
 
PART I: ABOUT YOURSELF 
 
1.   Sex  
Female    
Male                        
    
2.   Age?                 
        
3.  Weight?                       kgs      
    
4.   Height?                       cm   
                           
5.  What is your highest level of completed education?   
University/college………     Primary/secondary school… High school/A-levels…         
 
6.  Which county do you live in? ………………………………………… 
 
7.   Do you smoke?       
Daily                           
Once in a while                                  
Never                      
 
8.   Have you smoked on a daily basis before?   
Yes              
No         
  
9.   What is the aggregate pre-tax household income?  
                                                             
 
    
PART II: ABOUT YOUR DIABETES 
 
10. Which form of diabetes do you have?    
 (please select an alternative)           
Type 1…………………… Type 2……………………      
Other…………………… Uncertain…………………..  
 
13. What was your last HbA1c 
      blood sugar reading? 
 
11. In what year were you diagnosed with diabetes? 
 (please state year in digits) 
 
12. Has your diabetes led to any health-related problems/complications/associated diseases? (several answers 
possible)  
Inpaired vision……………………………………    
Cardiac infarction………………………………….  
Reduced renal function (protenuria)………  
Angina (chest pain associated with physical exertion))....  
Diabetic foot………………………………  
Stroke……………………………………..  
Amputation……………………………………  
…,…% 
If yes, please state  
number of years                      Years 
å
 
 
 
Renal transplantation……………………………  
Neuropathy (damage to the nerves)………………………..  
Uncertain…………………………………………  
No……………………………………………..  
Other, (please state), ……………………..………. 
 
 
 
PART III: DRUGS/MEDICATION 
 
14. Do you use any of the following drugs? (please check) 
Tablets: 
Actos …………….   
Glucobay ………..  
Amaryl ………….   
Glipizid……………….  
Apamid…………..   
Metformin …………….  
Avandia.................   
Minidiab ………………  
Avandamet ………   
Novonorm …………….  
Glibenclamid…….    
Starlix…………………  
Glucophage……..  
 
Insulin:  
Lantus …………….   
Insulin (long acting)…….  
Levemir ………….   
Insulin (short acting)…….  
 
15. Du you use any antihypertensive drugs? 
Yes  
No  
Uncertain  
 
16. Du you use any cholesterol-lowering drugs 
Yes  
No  
Not sure  
 
17. Do you use any other medications on a regular basis?  : 
Yes  
No  
Not sure……………………  ,  ………………… 
 
18. Have you experienced hypoglycemia in the course of the last 6 months? 
Yes  
No  
 
 
 
 
 
 
 
 
 
If yes, please state the number of times according to the description of the severity  
 
Transient hypoglycemia which goes away following the intake of e.g. a sugary drink without the assistance of next of 
kin/others……………………….times 
 
Transient hypoglycemia which goes away following the intake of e.g. a sugary drink with the assistance of next of 
kin/others ………………………. times 
 
Hypoglycemia requiring the attention of a doctor (without hospitalisation)…….      times 
 
Hypoglycemia with hospitalisation…….               times 
 
 
 
PART IV: DOCTOR AND HOSPITAL VISITS  
 
19. We will now ask you about your consumption of other health services in the course of the last 6 months. Please 
state the number of visits:   
 
General practitioner…………    times     
Nutritionist/dietician.                  times 
Specialist in private practice       times     
Foot therapist………                times  
Hospitalised….                      times    
Physiotherapist…….…              times  
Out-patient visits                       times    
Acupuncture………                  times 
 
20. If you have been hospitalised in the course of the last 6 months: For how long were you admitted? (please state 
the appropriate number of days in the table below (on a maximum of 8 occasions )).  
 
1st time…………                   days     
2nd time…………                  days 
3rd time………….                 days       
4th time………….                 days 
5th time…………..                days 
6th time…………..                days   
7th time…………..                days    
8th time…………..                days 
 
 
 
PART V: EQUIPMENT 
 
21. We will now inquire about your consumption of medical equipment associated with your diabetes in the course 
of the last 6 months.  
 
Do you use an insulin pump?  Yes        No     
 
State the number of items used in the course of the last 6 months: 
                       
Infusion set    Home measurement of  
(for insulin pump) ........                  urine ketones (self-tester)………                 
  
Home measurement                              Home measurement of 
of blood sugar (self-tester)........                              urine blood sugar (self-tester) ………                  
       
Insulin pens……                     Lancets for blood sugar measurement…….                 
 
Insulin pen needles......                  
 
 
 
 
 
 
 
 
 
PART VI: SICKNESS AND SOCIAL BENEFITS 
 
 
22. For how many weeks have you been away on sick leave in the course of the last 6 months  weeks   
 
23. Do you receive disability benefit? 
Yes                   
No    
 
24. Was diabetes the reason for your disability benefit 
Yes   
No  
Not sure   
 
25. Disability benefit degree  (please state percentage)                                % 
 
26. Do you receive basic benefit (grunnstønad), assistance benefit (hjelpestønad) or augmented assistance benefit 
(forhøyet hjelpestønad) from the National Insurance Administration due to diabetes? (please check, several 
answers possible) 
Basic benefit…………    
Augmented assistance benefit     
Assistance benefit………...    
No……………………  
 
27. If you reached maximum co-payment level 1 and were entitled to an Exemption Card (frikort)  during 2006, in 
which month was this?  
Please enter the number of the month here:                     
      
 
 
28. If you reached maximum co-payment level 2 and were entitled to an Exemption Card (frikort)  during 2006, in 
which month was this?         
Please enter the number of the month here:                     
 
 
 
 
PART VII: YOU AND YOUR FAMILY 
 
29. Does your diabetes make you dependent on your next of kin/family/close friends with regard to particular 
activities? (if yes, please check the relevant boxes in the table below, several answers possible) 
 
Administer injections ………   
Clean the house………..   
Tablet dosing …....   
Spend time outdoors………  
Cook……………   
 
 
30. Has anyone in your family had to take time off work to assist or support you in the course of the last 6 months 
as a consequence of your diabetes? 
Yes                   
No    
 
 
31. If yes, please state the number of days:                       days 
 
 
 
 
 
 
 
Januar   = 01 
Februar = 02 osv. 
Januar   = 01 
Februar = 02 osv. 
 
 
 
PART VIII: QUALITY OF LIFE 
We will now ask you some questions pertaining to quality of life. The questions below are drawn from a standard 
questionnaire used to measure quality of life associated with various health conditions. We would like to ask you to select 
the answer which best represents/fits/describes your  average condition over the last 6 months. 
   
32. Does diabetes affect your daily life? (if yes, select the box corresponding to the extent, in the table. Several 
answers are possible 1 means ”not at allt” while 5 is ”to a great extent”)  
 
         1 2 3 4 5 
I can’t eat whatever I like……………………..      
I suffer from fatigue………………………………      
I’m afraid of becoming hypoglycemic………………      
I’m afraid of my blood sugar level becoming too high       
I’m afraid of complications that might arise because of my diabetes …      
Diabetes limits my choice and pursuit of a career .…………..…      
Diabetes limits my leisure activities.………..      
Diabetes limits my participation in social activities and organisations…      
 
33. Mobility 
 
I have no problem walking around………..  
I have some problems walking around…………..  
I am bedridden……………………………….  
 
34. Self care 
 
I have no problems with regard to personal care………..  
I have some problems washing and/or dressing myself…...                               
I am unable to wash and or dress myself………………  
 
35. Usual activities (e.g. work, studies, household chores, and family or leisure activities). 
 
I have no problems with regard to my regular activities……..                           
I have some problems with regard to my regular activities…                            
I am unable to take part in any regular activities……………….                       
 
36. Pain and discomfort 
 
I experience neither pain nor discomfort……………….                                    
I experience moderate pain/discomfort……………..  
I experience strong pain/discomfort …………………  
 
37. Anxiety and depression  
 
I am neither anxious nor depressed……………..  
I am anxious/depressed to some degree………………....                                  
I am very anxious/depressed………………  
 
DO YOU HAVE ANY COMMENTS WITH REGARD TO OUR INVESTIGATION? IF SO,  PLEASE STATE 
THEM HERE 
__________________________________________________________________________________________________
__________________________________________________________________________________________________
__________________________________________________________________________________________________
__________________________________________________________________________________________________
__________________________________________________________________________________________________ 
Thank you for taking the time to answer our numerous questions! 
 
Please slip the questionnaire in the enclosed envelope and put it in the mail.  
 
 
 
 
Appendix 2 
 
 
 
The EQ-5D UK tariff value set 
 
UK VAS VALUE SET  Example:  
THE VALUE SET FOR HEALTH STATE 21232 
 
Full health (11111)       1 Full health 1 
 
At least one 2 or 3 (constant) - 0.155 Minus constant -0.155 
At least on 3 (N3) - 0.215 Minus N3 -0.215 
 
Mobility = 2 - 0.071 Minus MO level 2 -0.071 
Mobility = 3 - 0.182   
 
Self care = 2 - 0.093 Minus SC level 1 -0.000 
Self care = 3 - 0.145   
 
Usual activities = 2 - 0.031 Minus UA level 2 -0.031 
Usual activities = 3 - 0.081   
 
Pain/discomfort = 2 -0.084 Minus PD level 3 -0.171 
Pain/discomfort = 3 -0.171   
 
Anxiety/depression = 2 -0.063 Minus AD level 2 -0.063 
Anxiety/depression = 3 -0.124   
  STATE 21232 0.294 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3 
 
 
 
UKPDS Outcomes Model structure 
 
 
 
 
 
 
Source: Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ et al. A model to estimate the lifetime 
health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) 
Outcomes Model (UKPDS no. 68). Diabetologia 2004 October;47(10):1747-59. 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4 
 
 
 
UKPDS Outcomes Model equations – overview 
 
 
 
 
 
 
 
Source: Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ et al. A model to estimate the lifetime 
health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) 
Outcomes Model (UKPDS no. 68). Diabetologia 2004 October;47(10):1747-59. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5 
 
 
The event equations of the UKPDS Outcomes Model 
 
 Eq. 1 Eq. 2 Eq. 3 Eq. 4 Eq. 5 Eq. 6 Eq. 7 
Complication IHD MI CHF STROKE AMP BLIND RENAL 
No. of subjects 3612 3642 3607 3607 3642 3642 3642 
Functional 
form Weibull Weibull Weibull Weibull Weibull Weibull Weibull 
Parameters Estimate of coefficient (SE) 
 5.310 (0.174) 
4.977 
(0.160) 
8.018 
(0.408) 
7.163 
(0.342) 
8.718 
(0.613) 
6.464 
(0.326) 
10.016 
(0.939) 
 1.150 (0.067) 
1.257 
(0.060) 
1.711 
(0.158) 
1.497 
(0.126) 
1.451 
(0.232) 
1.154 
(0.121) 
1.865 
(0.387) 
AGE 0.031 (0.008) 
0.055 
(0.006) 
0.093 
(0.016) 
0.085 
(0.014)  
0.069 
(0.014)  
FEMALE 0.471 (0.143) 
0.826 
(0.103)  
0.516 
(0.171)    
AC  1.312 (0.341)      
SMOK  0.346 (0.097)  
0.355 
(0.179)    
BMI   0.066 (0.017)     
HBA1C 0.125 (0.035) 
0.118 
(0.025) 
0.157 
(0.057) 
0.128 
(0.042) 
0.435 
(0.066) 
0.221 
(0.050)  
SBP 0.098 (0.037) 
0.101 
(0.026) 
0.114 
(0.056) 
0.276 
(0.042) 
0.228 
(0.075)  
0.404 
(0.106) 
TOTAL:HDL    0.113 (0.025)    
Ln 
(TOTAL:HDL) 
1.498 
(0.202) 
1.190 
(0.169)      
PVD     2.436 (0.521)   
ATRFIB    1.428 (0.472)    
IHD  0.914 (0.150)      
CHF  1.558 (0.202)  
1.742 
(0.287)    
BLIND     1.812 (0.462)  
2.082 
(0.551) 
 
Source: Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ et al. A model to estimate the lifetime 
health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) 
Outcomes Model (UKPDS no. 68). Diabetologia 2004 October;47(10):1747-59. 
 
 
 
 
 
Appendix 6 
 
 
 
The mortality equations of the UKPDS Outcomes Model 
 
 Eq. 8 Eq. 9 Eq. 10 
Event EVENT FATALITY DIABETES MORTALITY OTHER DEATH
No. of subjects  717 584 3642 
Functional form  Logistic Gompertz Gompertz 
Parameters  Estimate of coefficient (SE)
 3.251 (0.358) 5.124 (0.363) 6.373 (0.162)
  0.003 (0.038) 0.154 (0.016) 
Ln (AGE_EVENT)  2.772 (0.716) 4.731 (1.066)  
AGE (FEMALE)    0.081 (0.013) 
AGE (1-FEMALE)    0.104 (0.012) 
SMOK    0.307 (0.141) 
HBA1C  0.114 (0.053)   
TOTAL:HDL   0.109 (0.047)  
MI_EVENT   2.640 (0.336) 3.939 (0.275)  
MI_POST   1.119 (0.277)  
STROKE_EVENT   1.048 (0.376) 2.807 (0.408)  
RENAL   1.585 (0.315)  
AMP   1.032 (0.377)  
 
Source: Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ et al. A model to estimate the lifetime 
health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) 
Outcomes Model (UKPDS no. 68). Diabetologia 2004 October;47(10):1747-59. 
 
 
 
 
Appendix 7  
 
 
 
The risk factor equations of the UKPDS Outcomes Model 
 
 Eq. 11 Eq. 12 Eq. 13 Eq. 14 
Risk factor  HBA1C SBP TOTAL:HDL SMOK 
No. of subjects     3631 3592 3520 3536 
Type of regression  Panel Panel Panel Logistic 
r2  0.64 0.65 0.44  
Parameters  Estimate of coefficient (SE)
 0.024 (0.017) 0.030 (0.014) 0.021 (0.007) 4.020 (0.236)
Ln (YEAR)  0.144 (0.009) 0.039 (0.008)   
YEAR     0.203 (0.024)
YEAR_2  0.333 (0.050)    
AGE     0.027 (0.008)
FEMALE     0.489 (0.154)
LHBA1C  0.759 (0.004)    
HBA1C_BASE  0.085 (0.004)    
LSBP   0.717 (0.004)   
SBP_BASE   0.127 (0.004)   
LTOTAL:HDL    0.526 (0.005)  
LTOTAL:HDL_BASE    0.252 (0.006)  
LSMOK     1.878 (0.211)
SMOK_BASE     4.879 (0.494)
 
Source: Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ et al. A model to estimate the lifetime 
health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) 
Outcomes Model (UKPDS no. 68). Diabetologia 2004 October;47(10):1747-59. 
